

IPR2017-00904  
Petition for *Inter Partes* Review

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

INNOPHARMA LICENSING, LLC,  
Petitioner

v.

ASTRAZENECA AB,  
Patent Owner

---

Case IPR2017-00904  
Patent No. 6,774,122

---

**PETITION FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 6,774,122  
UNDER 35 U.S.C. §§ 311-319 AND 37 C.F.R. § 42.100 *ET SEQ.***

Mail Stop: Patent Board  
Patent Trial and Appeal Board  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

I.	INTRODUCTION .....	1
II.	NOTICES, STATEMENTS AND PAYMENT OF FEES.....	4
	A. Real Party In Interest Under 37 C.F.R. § 42.8(b)(1) .....	4
	B. Related Matters Under 37 C.F.R. § 42.8(b)(2).....	4
	C. Lead and Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3).....	6
	D. Service Information Under 37 C.F.R. § 42.8(b)(4) .....	7
	E. Grounds for Standing Under 37 C.F.R. § 42.104(a).....	7
	F. Fees Under 37 C.F.R. § 42.103.....	7
III.	IDENTIFICATION OF CHALLENGE UNDER 37 C.F.R. § 42.104(B).....	7
IV.	INNOPHARMA’S GROUNDS OF UNPATENTABILITY ARE DISTINCT FROM THOSE PRESENTED BY MYLAN.....	9
V.	OVERVIEW OF THE ‘122 PATENT AND PROSECUTION HISTORY .	12
	A. The ‘122 Patent.....	12
	B. The Prosecution History .....	14
	1. The Prosecution History of the ‘122 Patent.....	14
	2. The Prosecution History of Related Applications .....	15
VI.	LEVEL OF ORDINARY SKILL IN THE ART.....	17
VII.	CLAIM CONSTRUCTION .....	17
	A. “Attained” .....	18
	B. “Therapeutically Significant” .....	18
	C. “Whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml <sup>-1</sup> is attained for at least 2 weeks after injection” .....	18

VIII. SCOPE AND CONTENT OF THE PRIOR ART.....	19
A. The Prior Art Discloses All Limitations of the Challenged Claims .....	19
1. Howell Closely Matches the Claimed Invention .....	19
2. McLeskey Discloses the Claimed Formulation and Was Not a “Treatment Failure” .....	22
3. O’Regan Confirms the Route of Administration .....	26
B. AstraZeneca’s Attempts to Detract From These Prior Art Teachings Fail .....	26
1. AstraZeneca’s Purported “Lead Compound” Analysis is Inapplicable .....	27
2. AstraZeneca’s Efficacy Arguments Are Contrary to Law.....	29
3. AstraZeneca’s Claims of Unpredictability Are Specious .....	30
a. The Pharmacokinetic Limitations Are Expressly Disclosed in the Prior Art.....	30
b. It Was Well-Known That Fulvestrant Was Administered Intramuscularly .....	32
c. The Claimed Combination of Excipients Were Neither Unexpected Nor Surprising .....	33
IX. DETAILED EXPLANATION AND SUPPORTING EVIDENCE.....	36
A. Ground 1: Claims 1, 2, 5, and 9 Are Obvious Over Howell .....	36
1. A POSA Would Have Been Motivated to Develop a Formulation to Achieve the Results Reported in Howell .....	36
2. A POSA Would Have A Reasonable Expectation of Success in Developing a Formulation to Achieve the Howell Results. ....	39
3. Every Limitation Is Disclosed By Howell And The Knowledge of a POSA.....	41

- B. Ground 2: Claims 1, 2, 5, and 9 Are Obvious Over Howell and McLeskey .....44
  - 1. A POSA Would Have Been Motivated to Combine Howell and McLeskey .....44
    - a. The Target Fulvestrant Concentration in Howell Would Have Led a Skilled Formulator to McLeskey.....44
    - b. The Record Confirms the Motivation to Combine Howell and McLeskey. ....47
  - 2. A POSA Would Have A Reasonable Expectation of Success in Administering the McLeskey Formulation Intramuscularly to Achieve the Results Reported in Howell .....51
  - 3. Each and Every Limitation Is Disclosed By the Combination of Howell and McLeskey .....57
- C. Ground 3: Claims 1, 2, 5, and 9 Are Obvious Over Howell, McLeskey, and O’Regan .....58
  - 1. A POSA Would Have Been Motivated to Combine Howell, McLeskey, and O’Regan.....59
  - 2. A POSA Would Have A Reasonable Expectation of Success in Combining Howell, McLeskey, and O’Regan.....59
  - 3. Each and Every Limitation Is Disclosed By the Combination of Howell, McLeskey, and O’Regan.....60
- X. SECONDARY CONSIDERATIONS, FAIL TO OVERCOME THE EVIDENCE OF OBVIOUSNESS. ....62
  - A. There Is No Nexus to the Claimed Invention .....62
  - B. AstraZeneca’s Secondary Considerations Arguments Fail .....64
    - 1. AstraZeneca Cannot Show Long-Felt Need .....64
    - 2. The Results Were Not Unexpected.....65
      - a. Dr. Robertson’s Arguments Are Contradicted By His Own

Published Work .....	65
b. The Release Profile and Effect of Benzyl Benzoate Were Expected .....	66
XI. CONCLUSION.....	66

**TABLE OF AUTHORITIES**

	Page(s)
<b>FEDERAL CASES</b>	
<i>Alcon Research, Ltd. v. Apotex Inc.</i> , 687 F.3d 1362 (Fed. Cir. 2012) .....	50
<i>Allergan, Inc. v. Apotex Inc.</i> , 754 F.3d 952 (Fed. Cir. 2014), <i>cert. denied</i> , 135 S. Ct. 956 (2015) .....	63
<i>Allergan, Inc. v. Sandoz Inc.</i> , 726 F.3d 1286 (Fed. Cir. 2013) .....	32
<i>Alza Corp. v. Mylan Labs., Inc.</i> , 464 F.3d 1286 (Fed. Cir. 2006) .....	29
<i>In re Applied Materials, Inc.</i> , 692 F.3d 1289 (Fed. Cir. 2012) .....	40
<i>AstraZeneca LP v. Breath Ltd.</i> , 603 F. App'x 999 (Fed. Cir. 2015) .....	64
<i>AstraZeneca Pharms. LP v. Agila Specialties, Inc.</i> , No. 1:15-cv-06039-RMB-KMW (D.N.J.) .....	4
<i>AstraZeneca Pharms. LP v. Dr. Reddy's Laboratories, Inc.</i> , No. 1:17-cv-926-RMB-KMW (D.N.J.) .....	5
<i>AstraZeneca Pharms. LP v. Glenmark Pharms. Inc., USA</i> , No. 1:15-cv-615 (D.N.J.) .....	5
<i>AstraZeneca Pharms. LP v. InnoPharma, Inc.</i> , No. 1:16-cv-894-RMB-KMW (D.N.J.) .....	4
<i>AstraZeneca Pharms. LP v. InnoPharma Licensing LLC</i> , No. 1:16-cv-1962-RMB-KMW (D.N.J.) .....	4, 5
<i>AstraZeneca Pharms. LP v. Mylan Institutional LLC</i> , No. 1:16-cv-4612-RMB-KMW (D.N.J.) .....	5

Petition for *Inter Partes* Review

<i>AstraZeneca Pharms. LP v. Mylan Pharms. Inc.</i> , No. 1:15-cv-7009-RMB-KMW (D.N.J.) .....	5
<i>AstraZeneca Pharms. LP v. Sagent Pharms., Inc.</i> , No. 1:14-cv-05539-RMB-KMW (D.N.J.) .....	5
<i>AstraZeneca Pharms. LP v. Sandoz Inc.</i> , No. 1:14-cv-03547-RMB-KMW (D.N.J.) .....	5
<i>AstraZeneca Pharms. LP v. Teva Parenteral Medicines Inc.</i> , No. 1:10-cv-18-JMS-KMW (D. Del.) .....	5
<i>AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc.</i> , No. 1:15-cv-7889-RMB-KMW (D.N.J.) .....	5
<i>Aventis Pharma S.A. v. Hospira, Inc.</i> , 743 F. Supp. 2d 305 (D. Del. 2010), <i>aff'd</i> , 675 F.3d 1324 (Fed. Cir. 2012) .....	35
<i>Cubist Pharms., Inc. v. Hospira, Inc.</i> , 805 F.3d 1112 (Fed. Cir. 2015), <i>cert. denied</i> , 136 S. Ct. 2393 (2016) .....	56
<i>Duramed Pharms., Inc. v. Watson Labs., Inc.</i> , 413 F. App'x 289 (Fed. Cir. 2011) .....	51
<i>In re Ethicon, Inc.</i> , 844 F.3d 1344 (Fed. Cir. 2017) .....	47
<i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013) .....	28, 31
<i>Hoffmann-La Roche Inc. v. Apotex Inc.</i> , 748 F.3d 1326 (Fed. Cir. 2014) .....	3, 29
<i>In re Huai-Hung Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011) .....	63
<i>In re ICON Health &amp; Fitness</i> , 496 F.3d 1374 (Fed. Cir. 2007) .....	37
<i>Iron Grip Barbell Co. v. USA Sports, Inc.</i> , 392 F.3d 1317 (Fed. Cir. 2004) .....	40

<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	47
<i>Merck &amp; Cie v. Gnosis S.P.A.</i> , 808 F.3d 829 (Fed. Cir. 2015) .....	31
<i>Merck &amp; Co. v. Biocraft Labs., Inc.</i> , 874 F.2d 804 (Fed. Cir. 1989) .....	28
<i>Merck &amp; Co. v. Teva Pharms. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005) .....	63
<i>Metso Minerals, Inc. v. Powerscreen Int'l Distrib., Ltd.</i> , 526 F. App'x 988 (Fed. Cir. 2013) .....	32
<i>Microsoft Corp. v. Multi-Tech Sys., Inc.</i> , 357 F.3d 1340 (Fed. Cir. 2004) .....	37
<i>Perfect Web Techs., Inc. v. InfoUSA, Inc.</i> , 587 F.3d 1324 (Fed. Cir. 2009) .....	64
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007) .....	41, 64
<i>PharmaStem Therapeutics, Inc. v. ViaCell, Inc.</i> , 491 F.3d 1342 (Fed. Cir. 2007) .....	33
<i>Purdue Pharma Prods. L.P. v. Par Pharm., Inc.</i> , 377 F. App'x 978 (Fed. Cir. 2010) .....	27
<i>Randall Mfg. v. Rea</i> , 733 F.3d 1355 (Fed. Cir. 2013) .....	37
<i>Santarus, Inc. v. Par Pharm., Inc.</i> , 694 F.3d 1344 (Fed. Cir. 2012) .....	55
<i>Smith &amp; Nephew, Inc. v. Rea</i> , 721 F.3d 1371 (Fed. Cir. 2013) .....	31
<i>Unigene Laboratories, Inc. v. Apotex, Inc.</i> , 655 F.3d 1352 (Fed. Cir. 2011) .....	28

**FEDERAL STATUTES**

35 U.S.C. § 102(b).....	8
35 U.S.C. § 103.....	7
35 U.S.C. §§ 311-19.....	1
35 U.S.C. § 325(d).....	9

**PETITIONER'S EXHIBIT LIST**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
<b>Exhibit 1001</b>	U.S. Patent No. 6,774,122 (“the ‘122 patent”)
<b>Exhibit 1002</b>	Complaint filed in <i>AstraZeneca Pharms. LP et al. v. InnoPharma, Inc.</i> , Case No. 1:16-cv-894 (D.N.J.)
<b>Exhibit 1003</b>	Proof of Service in <i>AstraZeneca Pharms. LP et al. v. InnoPharma, Inc.</i> , Case No. 1:16-cv-894 (D.N.J.)
<b>Exhibit 1004</b>	Order Dismissing Case Without Prejudice, <i>AstraZeneca Pharms. LP et al. v. InnoPharma, Inc.</i> , Case No. 1:16-cv-894 (D.N.J.)
<b>Exhibit 1005</b>	Complaint filed in <i>AstraZeneca Pharms. LP et al. v. InnoPharma Licensing, LLC</i> , Case No. 1:16-cv-1962 (D.N.J.)
<b>Exhibit 1006</b>	Copy of Prosecution History for U.S. Patent No. 6,774,122 (downloaded from PAIR)
<b>Exhibit 1007</b>	Howell et al., <i>Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer</i> , 74 BRIT. J. CANCER 300–08 (1996) (“ <b>Howell</b> ”)
<b>Exhibit 1008</b>	McLeskey et al., <i>Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors</i> , 4 CLIN. CANCER RESEARCH 697–711 (1998) (“ <b>McLeskey</b> ”)
<b>Exhibit 1009</b>	O’Regan et al., <i>Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth</i> , 90 J. NAT’L CANCER INST. 1552–1558 (1998) (“ <b>O’Regan</b> ”)
<b>Exhibit 1010</b>	Order, <i>AstraZeneca Pharms. LP v. Sandoz Inc.</i> , No. 14–03547 (D.N.J. July 29, 2015), ECF No. 102

<b>Exhibit 1011</b>	Institution Decision in <i>Mylan Pharms. Inc. v. AstraZeneca AB</i> , Paper No. 11, IPR2016-01325 (P.T.A.B. Dec. 14, 2016)
<b>Exhibit 1012</b>	Declaration of Diane Burgess, Ph.D. and Accompanying Exhibits
<b>Exhibit 1013</b>	Declaration of Richard Bergstrom, Ph.D. and Accompanying Exhibits
<b>Exhibit 1014</b>	Declaration of Dorraya El-Ashry, Ph.D. and Accompanying Exhibits
<b>Exhibit 1015</b>	Declaration of Adrian Harris, M.B., Ph.D. and Accompanying Exhibits
<b>Exhibit 1016</b>	U.S. Patent No. 4,659,516 (“the ‘516 patent”)
<b>Exhibit 1017</b>	AstraZeneca’s Preliminary Response in <i>Mylan Pharms. Inc. v. AstraZeneca AB</i> , Paper No. 10, IPR2016-01316 (P.T.A.B. Oct. 17, 2016)
<b>Exhibit 1018</b>	DeLuca, <i>Formulation of Small Volume Parenterals</i> , PHARMACEUTICAL DOSAGE FORMS: PARENTERAL MEDICATIONS VOLUME 1 (Avis ed., 2d ed. 1992)
<b>Exhibit 1019</b>	Declaration Under 37 C.F.R. § 1.132 of Ronald J. Sawchuk in Application No. 12/285,887
<b>Exhibit 1020</b>	Declaration Under 37 C.F.R. § 1.132 of Paul Richard Gellert in Application No. 10/872,784
<b>Exhibit 1021</b>	Faslodex <sup>®</sup> Label, available at: <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021344s019s020lbl.pdf">www.accessdata.fda.gov/drugsatfda_docs/label/2012/021344s019s020lbl.pdf</a>
<b>Exhibit 1022</b>	DiPiro, <i>Concepts in Clinical Pharmacokinetics</i> (2010)
<b>Exhibit 1023</b>	Qiu, <i>Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice</i> (2009)

<b>Exhibit 1024</b>	Tozer, <i>Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy</i> (2006)
<b>Exhibit 1025</b>	Caldwell, <i>An Introduction to Drug Disposition: The Basic Principles of Absorption, Distribution, Metabolism, and Excretion</i> , 23 <i>Toxicologic Pathology</i> 102 (1995)
<b>Exhibit 1026</b>	Wills, “Basic Pharmacodynamic Concepts and Models,” <i>Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology</i> (1994)
<b>Exhibit 1027</b>	Derendorf, <i>Handbook of Pharmacokinetic/Pharmacodynamic Correlation</i> 53 (1995)
<b>Exhibit 1028</b>	Mager, <i>Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans</i> , <i>DRUG METAB. PHARMACOKINET.</i> (2009)
<b>Exhibit 1029</b>	Colburn, <i>Simultaneous Pharmacokinetic/Pharmacodynamic Modeling</i> , <i>PHARMACODYNAMICS AND DRUG DEVELOPMENT: PERSPECTIVES IN CLINICAL PHARMACOLOGY</i> (1994)
<b>Exhibit 1030</b>	White, <i>Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization</i> , 57 <i>ANTIMICROBIAL AGENTS &amp; CHEMOTHERAPY</i> 5802 (2013)
<b>Exhibit 1031</b>	Wakeling et al., <i>A Potent Specific Pure Antiestrogen with Clinical Potential</i> , 51 <i>CANCER RESEARCH</i> 3867–3873 (1991) (“Wakeling 1991”)
<b>Exhibit 1032</b>	Nicholson, R.I. et al., <i>Responses To Pure Antiestrogens (ICI 164384, ICI 82780) In Estrogen-Sensitive And –Resistant Experimental And Clinical Breast Cancer</i> , <i>ANNALS OF THE NEW YORK ACADEMY OF SCIENCES</i> , Vol. 61:148-163 (1995) (“Nicholson”)

<b>Exhibit 1033</b>	Riffkin, <i>Castor Oil as a Vehicle for Parenteral Administration of Steroid Hormones</i> , 53 J. PHARM. SCI. 891–895 (1964) (“ <b>Riffkin</b> ”)
<b>Exhibit 1034</b>	Finley, <i>New Drug Being Tested in Breast Cancer Study</i> , SAN ANTONIO EXPRESS-NEWS, Sept. 20, 1997
<b>Exhibit 1035</b>	Uges, <i>Plasma or Serum in Therapeutic Drug Monitoring and Clinical Toxicology</i> , 10 PHARMACEUTISCH WEEKBLAD SCIENTIFIC EDITION 185–88 (1988) (“ <b>Uges</b> ”)
<b>Exhibit 1036</b>	Dukes et al., <i>Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys</i> , 135 J. ENDOCRINOLOGY 239–247 (1992) (“ <b>Dukes</b> ”)
<b>Exhibit 1037</b>	WO 03/006064
<b>Exhibit 1038</b>	DeFriend et al., <i>Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer</i> , 54 CANCER RESEARCH 408–414 (1994) (“ <b>DeFriend</b> ”)
<b>Exhibit 1039</b>	Osborne et al., <i>Comparison of the Effects of a Pure Steroidal Antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer</i> , 87 J. NAT’L CANCER INST. 746–750 (1995) (“ <b>Osborne 1995</b> ”)
<b>Exhibit 1040</b>	Alan E. Wakeling & Jean Bowler, <i>ICI 182,780: A New Antioestrogen with Clinical Potential</i> , 43 J. STEROID BIOCHEM. MOLEC. BIOL. 173–177 (1992) (“ <b>Wakeling 1992</b> ”)
<b>Exhibit 1041</b>	Howell, A. et al., <i>Clinical Studies With The Specific ‘Pure’ Antiestrogen ICI 182780</i> , THE BREAST, Vol. 5:192-195 (1996) (“ <b>Howell Breast 1996</b> ”)
<b>Exhibit 1042</b>	Copy of Prosecution History for U.S. Patent No. 8,329,680 (downloaded from PAIR)

<b>Exhibit 1043</b>	Robertson, J.F.R. et al., <i>Duration Of Remission To ICI 182,780 Compared To Megestrol Acetate In Tamoxifen Resistant Breast Cancer</i> , THE BREAST, Vol. 6:186-189 (1997) (“ <b>Robertson 1997</b> ”)
<b>Exhibit 1044</b>	Robertson, <i>Fulvestrant Versus Anastrozole for the Treatment of Advanced Breast Carcinoma in Postmenopausal Women: A Prospective Combined Analysis of Two Multicenter Trials</i> , 98 CANCER 229-38 (2003) (“ <b>Robertson 2003</b> ”)
<b>Exhibit 1045</b>	Howell, <i>Response to a Specific Antioestrogen (ICI 182780) in Tamoxifen-Resistant Breast Cancer</i> , 345 LANCET 989-90 (1995) (“ <b>Howell 1995</b> ”)
<b>Exhibit 1046</b>	Copy of Prosecution History for the U.S. Patent No. 7,456,160 (downloaded from PAIR)
<b>Exhibit 1047</b>	U.S. Patent No. 5,183,814 (“ <b>Dukes ‘814</b> ”)
<b>Exhibit 1048</b>	Parczyk, K. et al., <i>Progesterone Receptor Repression by Estrogens in Rat Uterine Epithelial Cells</i> , 63 J. STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY 309 (1997)
<b>Exhibit 1049</b>	Anderson, <i>Models of New Antioestrogen Action in Vivo: Primary Tumours</i> , 5 THE BREAST 186-91 (1996)
<b>Exhibit 1050</b>	Buzdar, <i>Update on Endocrine Therapy for Breast Cancer</i> , 4 CLINICAL CANCER RESEARCH 527-34 (1998)
<b>Exhibit 1051</b>	Howell, <i>New Endocrine Therapies for Breast Cancer</i> , 32A EUR. J. CANCER 576-88 (1996)
<b>Exhibit 1052</b>	Howell, <i>The Definition of the ‘No Change’ Category in Patients Treated with Endocrine Therapy and Chemotherapy for Advanced Carcinoma of the Breast</i> , 24 EUR. J. CANCER CLIN. ONCOL. 1567-72 (1988)

<b>Exhibit 1053</b>	Nicholson, “Pure Antioestrogens in Breast Cancer: Experimental and Clinical Observations,” <i>Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects</i> , Proceedings of an International Symposium, Milano 347-60 (1994) (“Nicholson”)
<b>Exhibit 1054</b>	Santen, <i>Use of Aromatase Inhibitors in Breast Carcinoma</i> , 6 ENDOCRINE-RELATED CANCER 75-92 (1999)
<b>Exhibit 1055</b>	EP 0 346 014
<b>Exhibit 1056</b>	Howell, <i>Response to a Specific Antioestrogen (ICI 182780) in Tamoxifen-Resistant Breast Cancer</i> , 345 LANCET 29-30 (1995)
<b>Exhibit 1057</b>	Dukes, <i>Antiuterotrophic Effects of the Pure Antioestrogen ICI 182,780 in Adult Female Monkeys (Macaca nemestrina): Quantitative Magnetic Resonance Imaging</i> , 138 J. ENDOCRINOLOGY 203-09 (1993)
<b>Exhibit 1058</b>	Wakeling, <i>The Future of New Pure Antioestrogens in Clinical Breast Cancer</i> , 25 BREAST CANCER RESEARCH & TREATMENT 1-9 (1993) (“Wakeling”)
<b>Exhibit 1059</b>	<i>Selective Estrogen Receptor Modulators (SERMs)</i> , BREASTCANCER.ORG (last modified Nov. 5, 2015), <a href="http://www.breastcancer.org/treatment/hormonal/serms">http://www.breastcancer.org/treatment/hormonal/serms</a>
<b>Exhibit 1060</b>	Howell, <i>Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose</i> , 11 CLINICAL BREAST CANCER 204-10 (2011)
<b>Exhibit 1061</b>	Thomas, <i>The Effects of ICI 182,780, a Pure Anti-Oestrogen, on the Hypothalamic—Pituitary—Gonadal Axis and on Endometrial Proliferation in Pre-Menopausal Women</i> , 9 HUMAN REPRODUCTION 1991-96 (1994)
<b>Exhibit 1062</b>	Freireich, <i>Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man</i> , 50 CANCER CHEMOTHERAPY REPORTS 219-44 (1966)

<b>Exhibit 1063</b>	Equivalent Surface Area Dosage Conversion Factors (2007)
<b>Exhibit 1064</b>	Clarke, <i>Antiestrogen Resistance in Breast Cancer and the Role of Estrogen Receptor Signaling</i> , 22 ONCOGENE 7316-39 (2003)
<b>Exhibit 1065</b>	Gusterson, <i>Do we now have a relevant animal model for breast cancer?</i> 1 BREAST CANCER RESEARCH 2-4 (1999)
<b>Exhibit 1066</b>	Johnston, <i>Changes in Estrogen Receptor, Progesterone Receptor, and pS2 Expression in Tamoxifen-Resistant Human Breast Cancer</i> , 55 CANCER RESEARCH 3331-38 (1995)
<b>Exhibit 1067</b>	Waynforth, <i>LASA Good Practice Guidelines: Administration of Substances (Rat, Mouse, Guinea Pig, Rabbit)</i> (Oct. 1998), <a href="http://www.procedureswithcare.org.uk/lasa_administration.pdf">www.procedureswithcare.org.uk/lasa_administration.pdf</a>
<b>Exhibit 1068</b>	Mackey, <i>Tolerability of Intramuscular Injections of Testosterone Ester in Oil Vehicle</i> , 10 HUMAN REPRODUCTION 862-65 (1995)
<b>Exhibit 1069</b>	Kern, "Role of Angiogenesis in the Transition to Hormone Independence and Acquisition of the Metastatic Phenotype," <i>Endocrinology of Breast Cancer</i> 169-86 (Manni ed., 1999)
<b>Exhibit 1070</b>	Neubauer, <i>Changes in Tumour Biological Markers during Primary Systemic Chemotherapy (PST)</i> , 28 ANTICANCER RESEARCH 1797-804 (2008)
<b>Exhibit 1071</b>	Smith, <i>Analysis of Oil-Based Pharmaceuticals</i> , 49 J. AMERICAN OIL CHEMISTS' SOCIETY 409-13 (1972)
<b>Exhibit 1072</b>	Spiegel & Noseworthy, <i>Use of Nonaqueous Solvents in Parenteral Products</i> , 52 J. PHARM. SCIS. 917-27 (1963) ("Spiegel")
<b>Exhibit 1073</b>	Taucher, <i>Sequential Steroid Hormone Receptor Measurements in Primary Breast Cancer with or without Intervening Primary Chemotherapy</i> , 10 ENDOCRINE-RELATED CANCER 91-98 (2003)

<b>Exhibit 1074</b>	Turner, <i>Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider</i> , 50 J. AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE 600-13 (2011)
<b>Exhibit 1075</b>	Robertson, J.F.R. et al., <i>A Partially-Blind, Randomised, Multicentre Study Comparing the Anti-Tumor Effects of Single Doses (50, 125 and 250 mg) Of Long-Acting (LA) 'Faslodex' (ICI 182,780) With Tamoxifen In Postmenopausal Women With Primary Breast Cancer Prior To Surgery</i> , in 22ND ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, Abstract No. 28 (Dec. 8-11, 1999) (“ <b>Robertson 1999</b> ”)
<b>Exhibit 1076</b>	Kohler, <i>Plasma and Tissue Concentrations Following Intramuscular Administration of Etofenamat. Pharmacokinetics of Etofenamat and Flufenamic Acid in Plasma, Synovium, and Tissues of Patients with Chronic Polyarthritits after Administration of an Oily Solution of Etofenamat</i> , 42 ARZNEIMITTEL-FORSCHUNG (English Abstract) (1992) (“ <b>Kohler</b> ”)
<b>Exhibit 1077</b>	Jorgensen, <i>Pharmacokinetic Studies in Volunteers of Intravenous and Oral Cis (Z)-Flupentixol and Intramuscular Cis (Z)-Flupentixol Decanoate in Viscoleo<sup>®</sup></i> , 18 EUR. J. CLIN. PHARMACOL. 355-60 (1980) (“ <b>Jorgensen</b> ”)
<b>Exhibit 1078</b>	Petition for <i>Inter Partes</i> Review in <i>Mylan Pharms. Inc. v. AstraZeneca AB</i> , Paper No. 1, IPR2016-01316 (P.T.A.B. June 29, 2016)
<b>Exhibit 1079</b>	<i>Handbook of Pharmaceutical Excipients</i> (Wade ed., 2d ed. 1994)
<b>Exhibit 1080</b>	FDA’s Inactive Ingredient Database (1996) (“ <b>IIG</b> ”)
<b>Exhibit 1081</b>	<i>Drugs@FDA Glossary of Terms</i> , U.S. FOOD & DRUG ADMINISTRATION (last updated Feb. 2, 2012), <a href="http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm">http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm</a>

<b>Exhibit 1082</b>	Adam, "Pharmacokinetics of Agents in Relation to Response," <i>Endocrine Management of Cancer: Biological Bases</i> 112-24 (1988)
<b>Exhibit 1083</b>	Baselga, <i>Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185<sup>HER2</sup> Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer</i> , 14 J. CLINICAL ONCOLOGY 737-44
<b>Exhibit 1084</b>	Fabian, <i>Clinical Pharmacology of Tamoxifen in Patients with Breast Cancer: Correlation with Clinical Data</i> , 48 CANCER 876-82 (1981)
<b>Exhibit 1085</b>	Goldenberg, <i>Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer</i> , 21 CLINICAL THERAPEUTICS 309-18 (1999)
<b>Exhibit 1086</b>	Wilkinson, <i>Tamoxifen (Nolvadex*) Therapy – Rationale for Loading Dose Followed by Maintenance Dose for Patients with Metastatic Breast Cancer</i> , 10 CANCER CHEMOTHERAPY PHARMACOLOGY 33-35 (1982)
<b>Exhibit 1087</b>	Copy of Prosecution History for the U.S. Patent No. 8,466,139 (downloaded from PAIR)
<b>Exhibit 1088</b>	Wunsche, <i>Estrogenic Regulation of Clusterin mRNA in Normal and Malignant Endometrial Tissue</i> , 76 INT. J. CANCER 684-88 (1998) ("Wunsche")
<b>Exhibit 1089</b>	Chwalisz, <i>Modulation of Oestrogenic Effects by Progesterone Antagonists in the Rat Uterus</i> , 4 HUMAN REPRODUCTION UPDATE 570-83 (1998) ("Chwalisz")
<b>Exhibit 1090</b>	Robertson, <i>Fulvestrant (Faslodex<sup>®</sup>)—How to Make a Good Drug Better</i> , 12 ONCOLOGIST 774-84 (2007)

<b>Exhibit 1091</b>	Ansel, "Dosage Form Design: Biopharmaceutic and Pharmacokinetic Considerations," <i>Pharmaceutical Dosage Forms and Drug Delivery Systems</i> 101-41 (7th ed. 1999)
<b>Exhibit 1092</b>	Lee, <i>Standard Deviation and Standard Error of the Mean</i> , 68 KOREAN J. ANESTHESIOLOGY 220-23 (2015)
<b>Exhibit 1093</b>	Altman, <i>Standard Deviations and Standard Errors</i> , 331 BMJ 903 (2005)
<b>Exhibit 1094</b>	Tse, <i>Bioavailability of Parenteral Drugs I. Intravenous and Intramuscular Doses</i> , 34 J. PARENTERAL DRUG ASSOCIATION 409-21 (1980)
<b>Exhibit 1095</b>	Licciardi, <i>Oral Versus Intramuscular Progesterone for In Vitro Fertilization: A Prospective Randomized Study</i> , 71 FERTILITY & STERILITY 614-18 (1999)
<b>Exhibit 1096</b>	August 21, 2008 Applicant Amendment and Response in Application No. 10/872,784
<b>Exhibit 1097</b>	Balant-Gorgia, <i>Pharmacokinetic Optimisation of the Treatment of Psychosis</i> , 25 CLIN. PHARMACOKINET. 217-36 (1993)
<b>Exhibit 1098</b>	Chien, <i>Solubilization of Steroids by Multiple Co-Solvent Systems</i> , 23 CHEM. PHARM. BULL. 1085-90 (1975)
<b>Exhibit 1099</b>	Ford, "Parenteral Products," <i>Pharmaceutics: The Science of Dosage Form Design</i> 359-80 (Aulton ed., 1988)
<b>Exhibit 1100</b>	Cunliffe-Beamer, "Biomethodology and Surgical Techniques," <i>The Mouse in Biomedical Research, Volume III: Normative Biology, Immunology, and Husbandry</i> 401-37 (Foster ed., 1983)
<b>Exhibit 1101</b>	Way, "Cosolvent Use in Injectable Formulations," <i>Injectable Drug Development: Techniques to Reduce Pain and Irritation</i> 215-66 (Gupta ed., 1999)

<b>Exhibit 1102</b>	Nema, <i>Excipients and Their Use in Injectable Products</i> , 51 PDA J. PHARM. SCI. & TECH. 166-71 (1997)
<b>Exhibit 1103</b>	Ogasawara, <i>Effects of Experimental Chemoendocrine Therapy with a Combination of a Pure Antiestrogen and 5-Fluorouracil on Human Breast Cancer Cells Implanted in Nude Mice</i> , 29 SURGERY TODAY 149-56 (1999)
<b>Exhibit 1104</b>	Oldham, "Mass Transport to Electrodes," <i>Chemical Kinetics</i> 79-143 (Bamford ed., 1986)
<b>Exhibit 1105</b>	Powell, <i>Compendium of Excipients for Parenteral Formulations</i> , 52 PDA J. PHARM. SCI. & TECH. 238-311 (1998)
<b>Exhibit 1106</b>	<i>Remington's Pharmaceutical Sciences</i> 1538-39, 1545-50, 1686-88 (18th ed. 1990)
<b>Exhibit 1107</b>	Roberts, <i>Investigation of Cosolvent Effects on the Solvation of AOT Reverse Micelles in Supercritical Ethane</i> , 102 J. PHYS. CHEM. B 9074-80 (1998)
<b>Exhibit 1108</b>	Sawka, <i>Physiological Consequences of Hypohydration: Exercise Performance and Thermoregulation</i> , 24 MEDICINE & SCIENCE IN SPORTS & EXERCISE 657-70 (1992)
<b>Exhibit 1109</b>	Simmons, <i>The Laboratory Mouse: Selection and Management</i> 127-28 (1970)
<b>Exhibit 1110</b>	Ting, <i>Solubility of Naproxen in Supercritical Carbon Dioxide with and without Cosolvents</i> , 32 IND. ENG. CHEM. RES. 1471-81 (1993)
<b>Exhibit 1111</b>	Tse, <i>Bioavailability of Parenteral Drugs II. Parenteral Doses Other Than Intravenous and Intramuscular Routes</i> , 34 J. PARENTERAL DRUG ASSOCIATION 484-95 (1980)
<b>Exhibit 1112</b>	U.S. Patent No. 4,212,863

IPR2017-00904

Petition for *Inter Partes* Review

<b>Exhibit 1113</b>	USP 23 – NF 18, The United States Pharmacopeia – The National Formulary 13-14 (1995)
---------------------	--

**TABLE OF ABBREVIATIONS**

7 $\alpha$ -[9-(4,4,5,5,5-pentafluoropentylsulphonyl)nonyl]oestra-1,3,5(10)- triene-3,17 $\beta$ -  
diol .....Fulvestrant

Estrogen receptor.....ER

Estrogen receptor-positive .....ER+ or ER-positive

Estrogen-receptor downregulators.....ERDs

Hormone-dependent.....HD

ICI 182,780.....Fulvestrant

Intramuscular .....IM

Percent volume in volume.....%v/v

Percent weight in volume.....%w/v

Person of ordinary skill in the art.....POSA

Selective estrogen-receptor modulators.....SERMs

Subcutaneous .....SC

U.S. Food and Drug Administration.....FDA

U.S. Patent and Trademark Office.....PTO

Petitioner InnoPharma Licensing, LLC (“Petitioner” or “InnoPharma”) requests *inter partes* review of claims 1, 2, 5, and 9 (“the challenged claims”) of U.S. Patent No. 6,774,122 (“the ‘122 patent”) (Ex. 1001) pursuant to 35 U.S.C. §§ 311-19 and 37 C.F.R. § 42.100.

## **I. INTRODUCTION**

The challenged claims should never have issued. They relate to a specific method for treating breast cancer with fulvestrant—a compound for which all patent protection has expired. And they do so in a manner that had been previously disclosed and touted for its efficacy. Indeed, the Board already found that two prior art references—McLeskey and Howell—“disclose[] each individual element of the claimed invention” when it considered a petition for *inter partes* review of U.S. Patent No. 8,329,680 (a continuation of the ‘122 patent) filed by Mylan Pharmaceuticals (“the Mylan ‘680 IPR”). Ex. 1011 at 0023. The sole question was whether Mylan had “adequately demonstrated” a motivation to combine the references or a reasonable expectation of success from that combination. *Id.* And the Board concluded that Mylan had not.

This Petition fills the gaps the Board identified and removes any doubt that there is a reasonable likelihood that the challenged claims are not patentable. It does so using new grounds, evidence, theories, and arguments that the Board never considered. The Board should, therefore, institute this proceeding and cancel the

claims that are improperly stifling generic competition for breast cancer treatment.

The claimed treatment method requires: (1) a 50 mg/ml concentration of fulvestrant, (2) a formulation with four excipients—castor oil, ethanol, benzyl alcohol, and benzyl benzoate, (3) an IM injection, and (4) certain specified amounts of the drug in the body at least two weeks after injection. This treatment method was nothing new. Howell had already reported “excellent” results from IM injections of a 50 mg/ml concentration of fulvestrant in a castor oil formulation that achieved the claimed blood concentrations for at least four weeks. And there was only one castor oil formulation in the prior art that had pharmaceutically acceptable excipients at levels previously approved by FDA and the ability to solubilize fulvestrant at the target 50 mg/ml concentration. That formulation was disclosed in McLeskey—and it is the exact same formulation recited in the challenged claims. A person motivated to achieve the promising results reported in Howell would necessarily use the McLeskey formulation.

With all the elements disclosed in on-point references that directly tie together, AstraZeneca has tried to rewrite history to introduce complexity that did not then exist. It was able to raise enough questions to avoid institution in the Mylan ‘680 IPR. It should not be so lucky this time. The Board identified the specific failures of proof that led to its decision—and they have been remedied here with new evidence that even includes a declaration from one of McLeskey’s

authors.

This time around, AstraZeneca's arguments should be rejected. They depend on revisionist history directly contradicted by contemporaneous evidence, including statements from AstraZeneca's own experts. For example, AstraZeneca now claims that the success of fulvestrant was entirely unpredictable—but then, its experts described fulvestrant as a “very exciting drug” that was “a prime candidate” for a further study as early as 1991.

AstraZeneca's arguments also rely on an ever-shifting story of what a POSA would do. One of its experts, for example, argues that a POSA would not have preferred a castor oil formulation, when another concedes that the only formulation a POSA would consider would be castor oil-based. The arguments also depend on theories that have been rejected by the Federal Circuit. AstraZeneca argues that its claims are saved because there was no conclusive proof of efficacy—even though the Federal Circuit has held that “conclusive proof of efficacy is not necessary to show obviousness.” *Hoffmann-La Roche Inc. v. Apotex Inc.*, 748 F.3d 1326, 1331 (Fed. Cir. 2014). Here, where the most fulsome fulvestrant study had shown positive results using the claimed method, there was a reasonable expectation of success.

The Board, therefore, should institute this proceeding and cancel the challenged claims as obvious.

**II. NOTICES, STATEMENTS AND PAYMENT OF FEES****A. Real Party In Interest Under 37 C.F.R. § 42.8(b)(1)**

InnoPharma Licensing, LLC, InnoPharma, Inc., and Pfizer Inc. are the real parties in interest. Additionally, out of an abundance of caution, Petitioner identifies each of Pfizer Australia Pty Ltd., Hospira Pty Ltd., and Hospira, Inc. as real parties in interest solely for this Petition and solely to the extent that Patent Owner contends that any of these separate legal entities should be named as real parties in interest in this IPR. Petitioner does not believe that Pfizer Australia Pty Ltd., Hospira Pty Ltd., and Hospira, Inc. are real parties in interest, but identifies them here as real parties in interest to avoid the potential expenditure of resources to resolve such a challenge. No unnamed entity is funding, controlling, or otherwise has an opportunity to direct or control this Petition or Petitioner's participation in any resulting IPR.

**B. Related Matters Under 37 C.F.R. § 42.8(b)(2)**

AstraZeneca has asserted the '122 patent in the litigations listed below:

- *AstraZeneca Pharms. LP v. Agila Specialties, Inc.*, No. 1:15-cv-06039-RMB-KMW (D.N.J.) (“the Consolidated Fulvestrant Action”);
- *AstraZeneca Pharms. LP v. InnoPharma, Inc.*, No. 1:16-cv-894-RMB-KMW (D.N.J.) (“the First InnoPharma Action”);
- *AstraZeneca Pharms. LP v. InnoPharma Licensing LLC*, No. 1:16-cv-1962-

RMB-KMW (D.N.J.) (part of the Consolidated Fulvestrant Action);

- *AstraZeneca Pharms. LP v. Sandoz Inc.*, No. 1:14-cv-03547-RMB-KMW (D.N.J.);
- *AstraZeneca Pharms. LP v. Sagent Pharms., Inc.*, No. 1:14-cv-05539-RMB-KMW (D.N.J.) and 1:14-cv-7358-EEC (N.D. Ill.);
- *AstraZeneca Pharms. LP v. Glenmark Pharms. Inc., USA*, No. 1:15-cv-615 (D.N.J.);
- *AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc.*, No. 1:15-cv-7889-RMB-KMW (D.N.J.)
- *AstraZeneca Pharms. LP v. Mylan Pharms. Inc.*, No. 1:15-cv-7009-RMB-KMW (D.N.J.);
- *AstraZeneca Pharms. LP v. Mylan Institutional LLC*, No. 1:16-cv-4612-RMB-KMW (D.N.J.);
- *AstraZeneca Pharms. LP v. Dr. Reddy's Laboratories, Inc.*, No. 1:17-cv-926-RMB-KMW (D.N.J.);
- *AstraZeneca Pharms. LP v. Teva Parenteral Medicines Inc.*, No. 1:10-cv-18-JMS-KMW (D. Del.).

Petitioner's parent company, InnoPharma, Inc., was a party to the First InnoPharma Action and was served with a Complaint no earlier than February 26,

2016. *See* Exs. 1002-1003. That Complaint was dismissed without prejudice on April 21, 2016. Ex. 1004. InnoPharma Licensing, LLC is a party to the Consolidated Fulvestrant Action and was first served with a Complaint on April 7, 2016. Ex. 1005.

On June 29, 2016, Mylan filed a petition for *inter partes* review of the ‘122 patent, *see* IPR2016-01316 (“the Mylan ‘122 IPR”), which was settled prior to an institution decision. IPR2016-01316, Paper No. 11. Mylan also filed a petition for *inter partes* review on the ‘680 patent, which is a continuation of the ‘122 patent. *See* IPR2016-01325. The Board denied institution, although it concluded that “each individual element of the claimed invention” was taught by the cited references. Ex. 1011 at 0023. As explained below, *see* § IV, the grounds for unpatentability in this Petition are different from those presented in the Mylan ‘122 IPR and the Mylan ‘680 IPR (collectively, “the Mylan IPRs”), and rely on different references, different evidence, and different claim constructions.

**C. Lead and Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3)**

InnoPharma designates lead and back-up counsel as noted below. Powers of attorney pursuant to 37 C.F.R. § 42.10(b) accompany this Petition.

Lead Counsel	Backup Counsel
Mark Pacella, Reg. No. 46,974	Karin Hessler, Reg. No. 62,523
WILEY REIN LLP 1776 K Street NW	

Washington, DC 20006 Phone: 202.719.7000 / Fax: 202.719.7049
---

**D. Service Information Under 37 C.F.R. § 42.8(b)(4)**

Please address all correspondence to counsel at the addresses above. Petitioner consents to electronic service by email at: [mpacella@wileyrein.com](mailto:mpacella@wileyrein.com) and [khessler@wileyrein.com](mailto:khessler@wileyrein.com).

**E. Grounds for Standing Under 37 C.F.R. § 42.104(a)**

Pursuant to 37 C.F.R. § 42.104(a), InnoPharma certifies that the '122 patent is available for *inter partes* review, and that Petitioner is not barred or estopped from requesting *inter partes* review based on the grounds herein.

**F. Fees Under 37 C.F.R. § 42.103**

Petitioner concurrently submits fees of \$23,000. If more fees are necessary to accord this Petition a filing date, authorization is granted to charge the same to Deposit Account No. 50-1129.

**III. IDENTIFICATION OF CHALLENGE UNDER 37 C.F.R. § 42.104(b)**

InnoPharma requests cancellation of claims 1, 2, 5, and 9 of the '122 patent as unpatentable under 35 U.S.C. § 103. This Petition, supported by the accompanying Declarations of Dr. Diane Burgess (Ex. 1012), Dr. Richard Bergstrom (Ex. 1013), Dr. Dorraya El-Ashry (Ex. 1014), and Dr. Adrian Harris (Ex. 1015), demonstrates that there is a reasonable likelihood that the challenged

claims are not patentable.

Pursuant to 37 C.F.R. §§ 42.22(a) and 42.104(b)(1)-(2), this challenge is based on the following references, all of which are prior art under 35 U.S.C. § 102(b):

1. **Howell (Exhibit 1007)**, *Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer*, BRITISH J. OF CANCER, 74, pp. 300-308, published in 1996—about 4 years before the January 2000 priority date of the ‘122 patent. Howell is cited on the face of the ‘122 patent but was not used during prosecution to substantively reject the claims.
2. **McLeskey (Exhibit 1008)**, *Tamoxifen-resistant Fibroblast Growth Factor-transfected MCF-7 Cells Are Cross-Resistant in Vivo to the Antiestrogen ICI 182,780 and Two Aromatase Inhibitors*, 4 CLIN. CANCER RESEARCH 697–711, published in 1998. McLeskey was not cited during prosecution of the ‘122 patent despite disclosing—as the Board has recognized—the “same formulation as recited in the present claims.” Exhibit 1011 at 0023.
3. **O’Regan (Exhibit 1009)**, *Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth*, 90 J. NAT’L CANCER INST. No. 20 1552–1558, published in 1998. O’Regan was not cited during prosecution of the ‘122 patent.

As explained below, InnoPharma requests that the Board cancel claims 1, 2, 5, and 9 based on the following grounds:

**Ground 1:** Claims 1, 2, 5, and 9 are obvious over Howell;

**Ground 2:** Claims 1, 2, 5, and 9 are obvious over Howell and McLeskey;

**Ground 3:** Claims 1, 2, 5, and 9 are obvious over Howell, McLeskey, and O'Regan.

**IV. INNOPHARMA'S GROUNDS OF UNPATENTABILITY ARE DISTINCT FROM THOSE PRESENTED BY MYLAN**

This Petition does not duplicate the Mylan IPRs. It relies on two new grounds of unpatentability—Grounds 1 and 3—which are by definition not “the same or substantially the same” as the Mylan grounds. 35 U.S.C. § 325(d). And the third ground—Ground 2—is also substantially different, because it is based on new evidence and argument, including the specific evidence that the Board found missing.

Ground 2 seeks cancellation of the claims as obvious over Howell and McLeskey, a combination that the Board found “discloses each individual element of the claimed invention.” Ex. 1011 at 0023. The Board nonetheless declined to institute review in the Mylan IPRs—but clarified that its decision was the result of specific gaps in the record. In particular, Mylan had not “adequately demonstrated” a motivation to combine the references or a reasonable expectation

of success from that combination. *Id.* This Petition cures these gaps in the record and sets forth substantially different reasons why the challenged claims are obvious over Howell and McLeskey.

Four differences highlight the distinctions between this Petition and the Mylan IPRs. *First*, this Petition changes the obviousness analysis by arguing that Howell—and not McLeskey—is the appropriate starting point for the combination. Howell closely mirrors the challenged claims and calls for a particular castor oil-based vehicle that a POSA would necessarily have looked to McLeskey to find. As a result, the Board’s concern that Mylan did not “adequately address why one of ordinary skill in the art would have selected McLeskey’s castor oil-based formulation as a starting point...” *id.* at 0024, is entirely inapplicable here.

*Second*, this Petition provides new evidence to answer questions the Board found were not resolved by the Mylan IPRs. For example, the attached Declaration of Dr. El-Ashry—an author of McLeskey and the lead ER expert on the project—corrects misrepresentations of McLeskey made by AstraZeneca that were left unrebutted in the Mylan IPRs. *See* Ex. 1014. Also attached are admissions made by Dr. Paul Gellert, AstraZeneca’s formulation scientist, that Mylan did not provide, but that confirm that a POSA would have taken certain routine steps as of the priority date, and that those steps render the challenged claims predictable. *See* Ex. 1020.

*Third*, this Petition, unlike the Mylan IPRs, systematically addresses each point raised by AstraZeneca's expert, Dr. Sawchuk, during prosecution of the '680 patent, *see supra* § IX(B)(2), and so cannot be criticized for "fail[ing] to adequately address the expert testimony and the other evidence cited in the Sawchuk § 1.132 Declaration...." *See* Ex. 1011 at 0027.

*Fourth*, this Petition fills every deficiency that the Board identified in the Mylan '680 IPR. Ex. 1011 at 0023. Included are reasons why the claims are obvious despite McLeskey's alleged "treatment failure," *see infra* § VIII(A)(2); Ex. 1012 ¶¶86; Ex. 1014 ¶¶54-58; McLeskey's supposed lack of efficacy or pharmacokinetics data, *see infra* § VIII(B)(3)(a); Ex. 1012 ¶¶215-18; Ex. 1013 ¶¶115-27; the claimed lack of predictability of formulation components and their physiological effect on the body, *see infra* § VIII(B)(3); Ex. 1012 ¶¶202-09, 213-18; Ex. 1013 ¶¶115-27; the purported inability to extrapolate between SC and IM injections, *see infra* § VIII(B)(3)(b), § IX(A)(2); Ex. 1012 ¶¶210-11; Ex. 1013 ¶¶125-26; Ex. 1015 ¶¶141-143, 167-72; and the ostensibly inadequate expectation of achieving the claimed blood plasma levels over weeks, *see infra* § VIII(B)(3)(a); Ex. 1012 ¶¶215-18; Ex. 1013 ¶¶115-27.

This Petition thus presents new and different evidence, makes new and different arguments, and provides at least two new rationales for combining Howell and McLeskey that are supported by controlling Federal Circuit law. It is

substantially different from the Mylan IPRs and should be instituted.

V. **OVERVIEW OF THE '122 PATENT AND PROSECUTION HISTORY**

A. **The '122 Patent**

The '122 patent relates to a method of treating hormone-dependent breast cancer using a sustained release formulation of fulvestrant but does not claim the fulvestrant active ingredient itself. Ex. 1001 at 12:55–14:15. As the '122 patent concedes, fulvestrant was patented and described more than a decade before the '122 patent and is no longer subject to patent protection. *Id.* at 2:32-45.

Fulvestrant belongs to a class of compounds known as steroidal antiestrogens, which work by binding to—or “antagonizing”—ERs found on breast cancer cells. *Id.* at 1:22-32. By antagonizing these receptors, fulvestrant prevents them from being stimulated by estrogen, stopping a known trigger of tumor growth. *Id.*

Steroidal antiestrogens were long known to be efficacious against “many benign and malignant diseases of the breast and reproductive tract.” *Id.* at 1:16-22. “The rationale for [their] design and testing” was first described in the 1980s. *Id.* at 1:43-46. Accordingly, there is extensive literature about formulation techniques for steroidal antiestrogens. The '122 patent, for example, states that “there are a number of sustained release injectable steroidal formulations which have been

commercialised,” including formulations that could achieve an extended release for as long as 8 weeks. *Id.* at 2:55-67.

Many of the prior art formulations include the same excipients recited in the challenged claims—benzyl benzoate, benzyl alcohol, and ethanol. *Id.* at 2:62-65. And the ‘122 patent itself cites at least six prior art formulations that used castor oil. *Id.* at Table 1. In its words, castor oil had been known to have a “greater solvating ability” for steroidal compounds since at least 1964—nearly forty years before the ‘122 patent’s earliest priority date. *Id.* at 5:19-25.

And more than a decade before that priority date, AstraZeneca’s initial formulations of fulvestrant—which closely track the ‘122 patent—were described and published. In 1988, for example, U.S. Patent No. 5,183,814 (“the ‘814 patent” or “Dukes”) described a formulation that taught the exact same concentration of fulvestrant (50 mg/ml) and a number of the same excipients (castor oil, benzyl alcohol) recited years later in the challenged claims. *Id.* at 3:60-67.

Given this crowded art, AstraZeneca’s purported point of novelty in the ‘122 patent was the supposed “surprising” discovery that adding benzyl benzoate increased the solubility of fulvestrant. *Id.* at 5:48-55. But benzyl benzoate was known in the art to “enhance steroid solubility in oils.” Ex. 1018 at 0027. Indeed, each of the commercially available castor oil-based formulations referenced in the ‘122 patent included benzyl benzoate. Ex. 1001 at Table 1. There was, therefore,

nothing “surprising” about benzyl benzoate.

**B. The Prosecution History**

1. The Prosecution History of the ‘122 Patent

Contrary to AstraZeneca’s claims, Howell and McLeskey were not “thoughtfully considered” by the Examiner during prosecution of the ‘122 patent. Ex. 1017 at 0001. In fact, McLeskey was not considered *at all*, and Howell was mentioned a single time in an information disclosures statement (“IDS”) filed by AstraZeneca. Ex. 1006 at 0461. Moreover, none of the Grounds identified in the instant Petition was cited by the PTO during the ‘122 prosecution.

Rather, the focus of the ‘122 prosecution was on the obviousness of the excipients in the formulation and the routine experimentation needed to optimize the concentrations of those excipients. Indeed, the PTO found that numerous aspects of the claims were known and well within the purview of a POSA:

- “One of ordinary skill in the art *would have been motivated to employ benzyl benzoate, ethanol, castor oil, and benzyl alcohol, in the herein claimed weight percent, with fulvestrant ...*”<sup>1</sup> *Id.* at 0538;
- “Castor oil and benzyl alcohol *are known to be effective* as vehicle for fulvestrant.” *Id.*;

<sup>1</sup> Unless otherwise noted, all emphases are added.

- “Ethanol is a *commonly used pharmaceutical solvent.*” *Id.*;
- “Benzyl benzoate is *known to be effective* as solvent for steroidal compounds.” *Id.*;
- “[C]ombining...benzyl benzoate, ethanol, castor oil, and benzyl alcohol, together and incorporat[ing] such combination with...fulvestrant, would be *reasonably expected to be useful in formulating a pharmaceutical composition.*” *Id.*;
- “One of ordinary skill in the art would have been motivated to maintain the plasma concentration of fulvestrant herein *because maintaining the therapeutic plasma level of the active compounds would be considered obvious....*” *Id.* at 0539.

Given the virtual identity between the POSA’s knowledge and the claimed invention, the PTO allowed the claims for one reason alone. *Id.* at 540-541. Specifically, the PTO found a purported “[u]nexpected increase of solubility of fulvestrant by adding 15% of benzyl benzoate into the composition”—a basis for patentability that could not stand had McLeskey been disclosed. *Id.* at 0540; *see also id.* at 0572. Neither AstraZeneca nor the PTO identified any other bases for patentability. *Id.* at 0572.

## 2. The Prosecution History of Related Applications

Like McLeskey, the Sawchuk Declaration that AstraZeneca touts (Ex. 1017

at 0009-0011) was not submitted during the '122 prosecution. It was submitted during the '680 prosecution, along with a declaration from another AstraZeneca witness, Dr. Paul Gellert, that contradicts it. *See* Ex. 1019; Ex. 1020. And it was Dr. Gellert—not Dr. Sawchuk—who had substantial formulation experience and was directly involved in the formulation of fulvestrant. Ex. 1020 ¶¶1-2. Dr. Gellert's declaration, as a result, provides the far more probative evidence about how a POSA "would likely have approached the task of developing a sustained release suitable for human use for a steroid composition such as fulvestrant in about early 2000." *Id.* ¶3.

The inconsistencies between the two declarations are many. For example, Dr. Sawchuk claims that "the *McLeskey castor oil composition* would have been among the *least favored compositions* to select for further development." Ex. 1019 ¶41. Dr. Gellert instead concluded "the experienced formulator *would have selected castor oil as the oil vehicle....*" Ex. 1020 ¶17. Dr. Sawchuk also believed that an oil suspension would have been "among *the most favored formulations* to select for further development," Ex. 1019 ¶41, when Dr. Gellert found that "suspensions...were *not an acceptable option for fulvestrant,*" Ex. 1020 ¶13. Dr. Sawchuk believed IM administration was unpredictable, Ex. 1019 ¶49, when Dr. Gellert conceded that a POSA would have targeted IM administration, Ex. 1020

¶11.

And Dr. Sawchuk admitted that he had “*not performed a search* for fulvestrant compositions known in the art,” Ex. 1019 ¶37, when Dr. Gellert explained that a POSA “*would have conducted a literature review.*” Ex. 1020 ¶14. Given these repeated contradictions and Dr. Sawchuk’s lack of formulation expertise, Dr. Sawchuk’s testimony—even if it had been submitted during the ‘122 prosecution—would be entitled to little to no weight. *See Covidien LP v. Ethicon Endo-Surgery, Inc.*, IPR2013-00209, Paper 28 at 11 (June 9, 2014) (finding contradictory expert testimony entitled to “less weight”).

#### **VI. LEVEL OF ORDINARY SKILL IN THE ART**

A POSA as of the January 2000 filing date of the ‘122 patent would have an advanced degree in pharmaceuticals, pharmacy, chemistry, medicine, or a related field, with at least three years of experience in analyzing the pharmacokinetics of drug formulations, developing and formulating dosage forms, and/or clinically treating or researching hormone dependent diseases of the breast. Ex. 1012 ¶¶41-42; Ex. 1013 ¶¶58-59; Ex. 1014 ¶¶17-18; Ex. 1015 ¶¶18-19. An individual need not have every qualification enumerated above. A multi-disciplinary team consisting of individuals with different skills and experience could suffice.

#### **VII. CLAIM CONSTRUCTION**

A claim subject to *inter partes* review receives the “broadest reasonable construction in light of the specification of the patent in which it appears.” 37

C.F.R. § 42.100(b). Throughout this Petition, InnoPharma applies the broadest reasonable construction.

A. “Attained”

Claims 1 and 2 recite the phrase “attained.” For purposes of this proceeding, “attained” should be construed to mean that **“the concentration of fulvestrant in a patient’s blood plasma is at or above the specified minimum concentration for the specified time period.”** This construction comports with the Board’s construction of the similar term “achieves” in the Mylan ‘680 IPR. Ex. 1011 at 0018, and is consistent with the claim language, Ex. 1001 at 12:55-65.

B. “Therapeutically Significant”

Claims 1 and 2 recite the phrase “therapeutically significant.” For purposes of this proceeding, “therapeutically significant” need not be expressly construed, which is consistent with the Board’s analysis in the Mylan ‘680 IPR. Ex. 1001 at 9:1-6; *see also* Ex. 1017 at 0033.

C. “Whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml<sup>-1</sup> is attained for at least 2 weeks after injection”

Claims 1 and 2 recite this phrase. For purposes of this proceeding—and consistent with the Board’s guidance in the Mylan ‘680 IPR—this phrase should be interpreted as a limitation. Ex. 1017 at 0033-0034.

## **VIII. SCOPE AND CONTENT OF THE PRIOR ART**

### **A. The Prior Art Discloses All Limitations of the Challenged Claims**

#### **1. Howell Closely Matches the Claimed Invention**

The Board recognized that Howell tracks the challenged claims. Ex. 1011 at 0021-0022. For good reason: AstraZeneca financially sponsored Howell and at least two of its authors were AstraZeneca employees. Ex. 1007 at 0001, 0007. Moreover, AstraZeneca later admitted that Howell—published about 4 years before the ‘122 patent’s priority date—utilized *the same long-acting castor oil-based formulation that AstraZeneca later sold and has claimed*. See Ex. 1044 at 0001-0002 (confirming after approval of Faslodex<sup>®</sup> that Howell utilized the “the current long-acting formulation” in the 1996 study).

Howell thus teaches a castor oil-based vehicle with the *same* injection volume (5 ml), the *same* concentration of fulvestrant (50 mg/ml), the *same* route of administration (IM), and the *same* sustained release profile as the challenged claims. Ex. 1007 at 0002, 0004 (“ICI 182780 was administered as a long-acting formulation contained in a castor oil-based vehicle by monthly i.m. injection (5 ml) into the buttock.”). In fact, Howell describes the sustained release profile using the very language that AstraZeneca now contends is covered by the challenged claims. Compare *id.* at 0001, 0006 (blood plasma concentration 2.5 ngml<sup>-1</sup> could be “*achieved and maintained* for 1 month...”) with Ex. 1017 at 0030 (“at least 2.5

ngml<sup>-1</sup> [could] be *achieved and maintained* for prolonged periods of time (namely, at least 2 weeks, 4 weeks, or 2-5 weeks)").

The results from Howell were indisputably promising. Ex. 1015 ¶¶115-20. Howell reported a "*high response rate* after tamoxifen failure," with 69% patients responding to the treatment. Ex. 1007 at 0005-0007. Howell also reported that "[n]o *serious drug-related adverse events occurred* in any of the 19 patients treated with ICI 182780" and that the "long-acting formulation of ICI 182780 used in this study appeared *well tolerated locally*...." *Id.* at 0004. The results of Howell were so positive that AstraZeneca's own expert witness, Dr. Robertson, touted it as "result[ing] in a *high response rate* and a *long median duration of remission*." Ex. 1043 at 0001. Similarly, another AstraZeneca expert, Dr. Osborne, described Howell's 69% response rates as "*much higher than you would expect from other forms of second-line hormonal therapies*." Ex. 1034 at 0001.

AstraZeneca's attempt to back away from these admissions should be rejected. *First*, AstraZeneca and its expert, Dr. Robertson, attempted to reduce the study's touted 69% response rate by excluding patients who did not experience a change in tumor size over the course of the study. Ex. 1017 at 0036; Robertson Decl. ¶174. But Dr. Robertson explained why it was so important to include those patients in the response rate when the Howell results were published:

Dowsett and co-workers point out that use of the no-change category

of response to endocrine therapy is uncommon. We showed that if patients had no change of their tumour growth for at least 6 months their final duration of response and overall survival did not differ significantly from that in patients who had a partial remission.... Thus, we feel that it is *important to recognise the no-change category of response since it is clinically relevant.*

Ex. 1045 at 0002.

*Second*, AstraZeneca and Dr. Robertson claimed that the consensus was to treat the results of Howell “with care.” But Dr. Robertson also disputed this characterization when Howell was published. *Id.* at 0001. He responded to the argument “that the high response rate that we reported...should be interpreted with care” by stating that the results instead “suggest that this hypothesis [that fulvestrant may be better than other endocrine therapies] is *worth pursuing.*” *Id.* at 0001-0002.

*Third*, AstraZeneca asserted that Howell was too “small” of a study to assess whether fulvestrant could have an effect on cancer progression. Ex. 1017 at 0035. But Howell was much more ambitious, describing the “aims of the study” as “assess[ing] the long-term efficacy and toxicity of the specific anti-oestrogen ICI 182780 in patients with advanced breast cancer and to evaluate the pharmacokinetics of the long-acting formulation used.” Ex. 1007 at 0001. In any

event, AstraZeneca fails to explain why a POSA would not have considered this study simply because of its size.

*Fourth*, AstraZeneca dismissed Howell because the patients were “highly selected.” Ex. 1017 at 0035-36. But in Howell, “highly selected” meant that the patients had “advanced breast cancer resistant to tamoxifen.” Ex. 1007 at 0002. Thus, this selection made sense, as the aim of the study was to assess fulvestrant treatment in patients with advanced breast cancer. *Id.* at 0001.

2. McLeskey Discloses the Claimed Formulation and Was Not a “Treatment Failure”

The Board already accepted that “McLeskey discloses the same formulation as recited in the present claims” based on the record in the Mylan ‘680 IPR. Ex. 1011 at 0023. The Board’s conclusion is unsurprising: McLeskey received “preformulated” fulvestrant *directly from AstraZeneca*. Ex. 1008 at 0002.

With McLeskey directly on-point, AstraZeneca tried to discount it in the Mylan IPRs as evidence of a “treatment failure[.]” Ex. 1017 at 0035. It was not. This Petition includes new evidence provided by Dr. El-Ashry—co-author and lead ER expert on the project—explaining that a POSA would understand that fulvestrant performed successfully and as intended in McLeskey. Ex. 1014.

The purpose of McLeskey was to better understand why certain types of ER+ breast cancers were resistant to known estrogen-receptor antagonists such as

tamoxifen. *Id.* ¶38. By understanding the mechanism of resistance, clinicians could more effectively treat *both* hormone-dependent and hormone-independent breast cancer. *Id.* ¶¶65-66.

The McLeskey authors hypothesized that a growth factor known as fibroblast growth factor (“FGF”) may be “replacing estrogen as a . . . stimulus for tumor growth” in these treatment-resistant cancer cells. Ex. 1008 at 0001. To confirm that hypothesis, the authors injected “MCF-7”—the standard human breast cancer cell line—into mice lacking ovaries. *Id.* The McLeskey authors modified that cell line to overexpress the FGF thought to be stimulating tumor growth. Ex. 1014 ¶39. This modified cell line is referred to in McLeskey as the “FGF-transfected MCF-7 cell line.” *Id.* ¶39.

To test whether it was, in fact, FGF and not estrogen that was stimulating tumor growth, the McLeskey authors administered the best-known and efficacious antiestrogens at the time—which included fulvestrant—to “*abrogate all estrogenic activity*” in the FGF-transfected MCF-7 cell line. Ex. 1008 at 0010. As McLeskey acknowledges, fulvestrant was known at the time to be a “pure antiestrogen” that could successfully inhibit growth. Ex. 1008 at 0004; Figures 4, 5.

Fulvestrant did its job. Ex. 1017 at 0035. Indeed, Figure 8 of McLeskey confirms that fulvestrant successfully blocked ERs in the FGF-transfected MCF-7 cell line, Ex. 1014 ¶¶ 45, 50, 52, allowing the McLeskey authors to reliably

conclude that tumor growth in the FGF-transfected MCF-7 cell line was being stimulated by FGF and not by estrogen. *Id.* ¶50.

Therefore, and as Dr. El-Ashry explains, a POSA would not have discounted McLeskey solely because the FGF-transfected MCF-7 cell lines were resistant to fulvestrant. *Id.* ¶¶50-52. As the McLeskey authors concluded, the cell line was resistant because the modifications they introduced caused the ER to be *entirely bypassed* in the FGF-mediated tumor growth pathway. *Id.* ¶51. Thus, the outcome in McLeskey was not due to fulvestrant, but rather a consequence of FGF overexpression. *Id.* ¶58.

AstraZeneca's remaining criticisms of McLeskey are equally meritless. *First*, AstraZeneca has claimed that a POSA would conclude that the formulations disclosed in McLeskey would only be administrable to animals because the testing was performed on mice. Ex. 1017 at 0035. But the formulations that AstraZeneca relies on to support its argument—tamoxifen pellets and an oral letrozole gavage—are not the formulation at issue here. Rather, these are formulations of drugs that are typically administered orally in the clinical setting and necessarily need to be specially formulated for administration to mice.<sup>2</sup> Ex. 1014 ¶¶60-61. A POSA

---

<sup>2</sup> Oral solid dosage forms have to be given to mice in their food and water, which introduces dosing uncertainty and variability. Ex. 1014 ¶¶59-60. Thus, mice

would have understood that the other formulation in *McLeskey*—the oil-based formulation at issue here—would be appropriate for human use, consistent with other oil-based depots that had previously been administered to mice and humans. *Id.* ¶60. Indeed, the formulation had been obtained *preformulated* from AstraZeneca, a company specializing in human pharmaceuticals. Ex. 1008 at 0002.

*Second*, AstraZeneca argues that a POSA would have disregarded *McLeskey* because it focused on hormone-independent breast cancer. Ex. 1017 at 0034, 0053. This argument misunderstands both *McLeskey* and the nature of breast cancer research and treatment. Ex. 1014 ¶¶65-66. A POSA would have already known that fulvestrant is an effective treatment for hormone-dependent cancer. Ex. 1015 ¶¶75, 77. The POSA would not discount that evidence based on *McLeskey*, which utilized fulvestrant in a modified, overexpressed cell line as a control. Ex. 1014 ¶¶39, 50.

Moreover, in order to effectively treat breast cancer, the POSA must understand *both* the hormone-dependent and hormone-independent pathways in order to select the appropriate treatment and accurately predict patient response.

---

typically receive different formulations of oral drugs than those administered to humans to in order to eliminate that variability problem. *Id.* ¶60.

*Id.* ¶¶65-66. A POSA would not have ignored research directed toward one type of cancer or the other, particularly in the context of fulvestrant, which was a known second line therapy for use after another therapy failed. Understanding the resistance mechanism would therefore have been crucial in determining whether treatment by fulvestrant was appropriate. *Id.* ¶¶65-66.

3. O'Regan Confirms the Route of Administration

Like McLeskey, O'Regan was never considered during the prosecution of the '122 patent. If there was any question concerning the proper route of administration for fulvestrant in humans—despite the fact that Howell used IM administration with success—O'Regan succinctly answered it more than two years before the earliest priority date. O'Regan expressly disclosed that “[c]linically, [fulvestrant] *must be given by depot intramuscular injection* because of low oral potency.” Ex 1009 at 0002. Importantly, O'Regan drew this conclusion despite the fact that she injected fulvestrant subcutaneously in mice in her study. *Id.* at 0002.

B. AstraZeneca's Attempts to Detract From These Prior Art Teachings Fail

In its preliminary response to the Mylan IPRs, AstraZeneca relied on untenable arguments that contradict its own documents and statements. In addition to the flawed arguments detailed above, *see* § VIII(A), AstraZeneca has asserted

that: (1) a POSA—despite recognizing that fulvestrant was “*excellent*” and “*much better than tamoxifen*”—would have ignored fulvestrant as a treatment option; (2) absolute proof of efficacy in humans is required; and (3) vague “unpredictability” about fulvestrant precluded its further development. These arguments uniformly fail.

1. AstraZeneca’s Purported “Lead Compound” Analysis is Inapplicable

In the Mylan ‘680 IPR, the Board properly disregarded AstraZeneca’s attempt to re-cast fulvestrant as a “tainted” drug that was apparently inferior to “at least 15 other more promising candidates” and would not have served as a starting point for a POSA. Ex. 1017 at 0039-0040. AstraZeneca’s argument is contrary to the law and facts.

Legally, the Federal Circuit has repeatedly rejected AstraZeneca’s argument. In *Purdue Pharma*, the patent owner argued that a POSA “would not have selected tramadol out of the myriad other possible active ingredients for use in a once-daily formulation.” *Purdue Pharma Prods. L.P. v. Par Pharm., Inc.*, 377 F. App’x 978, 982 (Fed. Cir. 2010). The Court disagreed, finding that the prior art’s disclosure of tramadol “as one of fourteen different opioid analgesics” had “render[ed] the selection of tramadol obvious[,] regardless whether or not the patent lists tramadol as a preferred embodiment.” *Id.* The Federal Circuit reached the same conclusion

in *Merck & Co. v. Biocraft Labs., Inc.*, 874 F.2d 804, 807 (Fed. Cir. 1989), finding that the fact that a reference “discloses a multitude of effective combinations does not render any particular formulation less obvious.” And the Federal Circuit reached that conclusion even though prior art expressed a preference for one of the alternatives, which is not present here. See *Galderma Labs., L.P. v. Tolmar, Inc.*, 737 F.3d 731, 739 (Fed. Cir. 2013) (“A teaching that a composition may be optimal or standard does not criticize, discredit, or otherwise discourage investigation into other compositions.”).<sup>3</sup>

Factually, AstraZeneca’s argument fails because it is premised on an assertion that fulvestrant’s properties were unknown. Contemporaneous evidence—including statements from AstraZeneca’s experts—show that was not true. Ex. 1015 ¶¶76-93. For example, a 1994 study found that fulvestrant “*produced demonstrable antiestrogenic effects in human breast tumors in*

---

<sup>3</sup> *Unigene Laboratories, Inc. v. Apotex, Inc.*, 655 F.3d 1352, 1363 (Fed. Cir. 2011), cited by AstraZeneca, is not to the contrary. As this Board recognized, “in *Unigene*, the component alleged to be obvious to substitute ‘ha[d] a vague role in even the closest prior art.’” *Ex Parte Eldon Q. Farnes*, Appeal 2015-002600, 2016 WL 5957931, at \*4 (P.T.A.B. Oct. 11, 2016) (citation omitted). Here, each component in the formulation had a well-known purpose. Ex. 1012 ¶22.

*vivo....*” Ex. 1038 at 0001. AstraZeneca’s expert, Dr. Robertson, then described fulvestrant as “the *most advanced of a new class of drugs.*” Ex. 1075 at 0003. And Dr. Osborne, another AstraZeneca expert, proclaimed in 1997 that fulvestrant was a “*very exciting drug*” that was “*much better than tamoxifen.*” Ex. 1034 at 0001. AstraZeneca’s attempt to rewrite history should be rejected, especially in light of the promising results from Howell. Ex. 1007 at 0007.

## 2. AstraZeneca’s Efficacy Arguments Are Contrary to Law

AstraZeneca’s argument that a POSA would not have considered fulvestrant because of some purported “unproven efficacy” is also at odds with Federal Circuit law. Ex. 1017 at 0018. The Federal Circuit has made clear that “*conclusive proof of efficacy is not necessary to show obviousness.* All that is required is a *reasonable expectation of success.*” *Hoffmann-La Roche*, 748 F.3d at 1331; *Alza Corp. v. Mylan Labs., Inc.*, 464 F.3d 1286, 1295 (Fed. Cir. 2006).

And, in any event, fulvestrant’s efficacy was not “unproven.” It was then known to be “a *potent and specific inhibitor* of estrogen action and demonstrated *excellent* growth-inhibitory effects.” Ex. 1031 at 0001. And its efficacy had been demonstrated in at least two clinical trials. *See* Ex. 1038 at 0001; Ex. 1007 at 0007. Thus, a POSA would have had a reasonable expectation of success in using fulvestrant to treat hormone-dependent breast cancer. Ex. 1015 ¶¶76-93, 162.

3. AstraZeneca's Claims of Unpredictability Are Specious

Finally, AstraZeneca has suggested that: (a) the pharmacokinetic limitations; (b) the route of administration; and (c) the claimed combination of excipients in the '122 patent were "unexpected" and "surprising." These arguments are also flawed.

a. The Pharmacokinetic Limitations Are Expressly Disclosed in the Prior Art

Howell expressly discloses the claimed therapeutically significant blood plasma levels using the same language that AstraZeneca later used in the '122 patent. Despite this explicit teaching, AstraZeneca remarkably asserts that Howell somehow "teaches away" from these claimed blood levels based on an isolated snippet of Howell that it takes out of context. Ex. 1017 at 0020. Howell does not "teach away" from the '122 patent for at least four reasons.

*First*, AstraZeneca argues that Howell teaches away because it speaks of lowering blood fulvestrant concentration levels. But Howell says nothing about lowering blood levels. Instead, Howell hypothesizes lowering the *dose* to achieve the *same* blood levels. Ex. 1007 at 0006. Howell thus provided motivation to continue to pursue its teachings. *Id.*

*Second*, Howell's discussion of lower doses cannot teach away from the '122 patent because dosage is *not* a limitation in any challenged claim. Instead, the claims only require achieving and maintaining a plasma concentration of 2.5

ng/ml, which Howell explicitly teaches.<sup>4</sup> It is black letter law that nonobviousness cannot be premised on unclaimed limitations. *See, e.g., Smith & Nephew, Inc. v. Rea*, 721 F.3d 1371, 1377, 1380-81 (Fed. Cir. 2013) (error to find nonobviousness based on a feature not required by the asserted claims).

*Third*, AstraZeneca cannot show that Howell teaches away from the challenged claims by pointing to one isolated snippet divorced from all context. Teaching away instead requires a showing based on the prior art *as a whole*. *See Merck & Cie v. Gnosis S.P.A.*, 808 F.3d 829, 834 (Fed. Cir. 2015) (rejecting reliance on “isolated prior art disclosures” for teaching away).

*Fourth*, even if Howell did suggest a way to lower blood levels through lower doses, it would not teach away. Howell states only that a lower dose “*may* be effective...although further clinical studies are required to confirm.” Ex. 1007 at 0006. That does not discourage investigation into the claimed invention, and so does not teach away. *See Galderma*, 737 F.3d at 738.

*Finally*, AstraZeneca has argued that the invention was unpredictable because a pharmacokinetic-pharmacodynamic link was “not proven” by Howell. Ex. 1017 at 0036. But the claims do not require any particular pharmacodynamic

---

<sup>4</sup> While Howell discloses serum concentrations, serum and plasma concentrations for fulvestrant should be the same. Ex. 1013 ¶ 82 n.3.

link. They instead only require—as AstraZeneca’s claim construction makes clear—specific fulvestrant blood concentrations. *See Metso Minerals, Inc. v. Powerscreen Int’l Distrib., Ltd.*, 526 F. App’x 988, 996-97 (Fed. Cir. 2013) (“Since there was no requirement of a ‘stop’ in the ’618 patent, whether the prior art taught a ‘stop’ is irrelevant”).

b. It Was Well-Known That Fulvestrant Was Administered Intramuscularly

AstraZeneca has also claimed that the IM route of administration was unpredictable. But O’Regan expressly taught that “[c]linically, [fulvestrant] *must be given by depot intramuscular injection* because of low oral potency.” Ex. 1009 at 0002. Despite this express disclosure, AstraZeneca posits that a POSA would have pursued at least six routes of administration with “thousands of different excipients,” and would have ultimately preferred an oral formulation. Ex. 1017 at 0043.

“[F]ormulation science carries with it a degree of unpredictability,” but “obviousness cannot be avoided simply by a showing of some degree of unpredictability in the art.” *Allergan, Inc. v. Sandoz Inc.*, 726 F.3d 1286, 1292 (Fed. Cir. 2013) (citation omitted). And here, there was more than a reasonable probability of success in the IM administration of fulvestrant. The most advanced clinical trial at the time—Howell—used that *exact* route of administration. Ex.

1007 at 0002. It did so, as the authors of Howell acknowledged, because fulvestrant “*was not considered to be bioavailable in an oral form.*” Ex. 1041 at 0002; Ex. 1040 at 0004. AstraZeneca’s argument, then, casts an already-rejected oral route of administration as the vastly preferred technique. Instead, the far more reasonable expectation of success was with the previously successful IM route.

c. The Claimed Combination of Excipients Were Neither Unexpected Nor Surprising

AstraZeneca lastly suggested that the chosen excipients were somehow “unconventional.” Ex. 1017 at 0046. This too fails.

As a threshold matter, AstraZeneca’s specification confirms that the claimed excipients were commonly used in commercialized steroidal depot formulations. Ex. 1001 at Table 1 & 2:55-67 (“In the formulations within Table 1 [commercialized steroid depot formulations] a number of different *oils* are used to solubilise the compound and *additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used*”). This admission is binding for obviousness purposes. See *PharmaStem Therapeutics, Inc. v. ViaCell, Inc.*, 491 F.3d 1342, 1362 (Fed. Cir. 2007) (“Admissions in the specification regarding the prior art are binding on the patentee for purposes of a later inquiry into obviousness”).

Consistent with AstraZeneca’s admission, Dr. Gellert conceded during prosecution that a POSA developing a fulvestrant formulation “would have

selected castor oil as the oil vehicle” and that “ethanol and/or benzyl alcohol would have been seen as the *best co-solvent candidates* for raising the fulvestrant solubility to the 45 mg/mL target...” Ex. 1020 ¶¶17, 21; *see also* Ex. 1046 at 0158 (referencing the “very high solubility of fulvestrant in benzyl alcohol and ethanol,” and concluding that “adding an alcohol component to the castor oil *would be seen as a clear choice to the skilled person*”); *see* Ex. 1001 at Table 1.

Similarly, for benzyl benzoate, Dr. Gellert admitted that “[a] number of the commercialized formulations that would have been identified in [a] literature review (including the castor oil-based formulations) have a *substantial benzyl benzoate component*.” Ex. 1020 ¶18. Dr. Gellert’s statement closely aligns with the contemporaneous literature, which recognized that benzyl benzoate could be used to enhance solubility in steroid formulations. *See, e.g.*, Ex. 1018 at 0027 (“Benzyl benzoate may be used to enhance steroid solubility in oils”). Thus, it is clear that each and every excipient used by AstraZeneca was conventional.

AstraZeneca tries to create unpredictability by arguing that the choice and amount of excipients can unpredictably result in side effects in the muscle. Ex. 1017 at 0049. Although the Board briefly considered this argument in the Mylan ‘680 IPR, Mylan had not adduced any evidence on the issue. Ex. 1011 at 0028. The evidence and argument submitted with this Petition, in contrast, establishes at least three reasons why AstraZeneca is wrong.

*First*, AstraZeneca's argument again improperly relies on an unclaimed feature in an attempt to show nonobviousness. *See Aventis Pharma S.A. v. Hospira, Inc.*, 743 F. Supp. 2d 305, 343 (D. Del. 2010), *aff'd*, 675 F.3d 1324 (Fed. Cir. 2012) (finding assertions regarding the possible toxicity unavailing because the asserted claims contain no limitations regarding toxicity). Here, the challenged claims are silent on any requirement concerning a particular side effect profile, and so cannot avoid an obviousness finding on that basis.

*Second*, the side effects from the excipients were predictable. As of the priority date of the '122 patent, castor oil, ethanol, benzyl alcohol, and benzyl benzoate had been approved by FDA as safe for IM use in humans at or above the concentrations recited in McLeskey and the challenged claims. Ex. 1012 ¶147. As AstraZeneca's Dr. Gellert acknowledged, "a knowledge of which excipients have been deemed safe by the FDA or are already present in a marketed product provides increased assurance to the formulator that these excipients will probably be safe for their new drug product." Ex. 1020 ¶14. Thus, a POSA would expect that if the excipients were used at or below the previously approved levels, they would not produce adverse events upon IM injection. Ex. 1012 ¶147.

*Third*, the reference that AstraZeneca relies on—Riffkin—does not support its argument. Riffkin tested its formulations in rabbits, which it concedes is *not predictive of muscle damage in humans*. Ex. 1033 at 0004 ("Although rabbit

muscles are more sensitive than human muscles, they were selected primarily because local changes in the muscle were observed easily. *It was not always possible, however, to correlate muscle irritation in animals to that of humans*”).

The claims here are limited to humans—as AstraZeneca has stressed repeatedly—meaning that Riffkin does not create any “uncertainty” related to muscle damage.

#### **IX. DETAILED EXPLANATION AND SUPPORTING EVIDENCE**

Pursuant to 37 C.F.R. §§ 42.104(b)(4) and (b)(5), InnoPharma sets forth an explanation below of why claims 1, 2, 5, and 9 are unpatentable under the identified grounds.

##### **A. Ground 1: Claims 1, 2, 5, and 9 Are Obvious Over Howell**

As explained below, each and every limitation of claims 1, 2, 5, and 9 is taught by Howell in view of the knowledge of a POSA.

##### **1. A POSA Would Have Been Motivated to Develop a Formulation to Achieve the Results Reported in Howell**

A POSA would have been motivated to develop a fulvestrant formulation that would achieve the positive results reported in Howell. *See supra* § VIII(A)(1); Ex. 1007 at 0005; Ex. 1015 ¶¶115-34. In particular, Howell taught that monthly IM injections of a castor oil-based formulation resulted in a 69% response rate and a “long median duration of remission.” *See supra* § VIII(A)(1).

As a result, Howell would have been the logical starting point for any POSA interested in developing a method for treating hormone-dependent breast cancer

with fulvestrant. Ex. 1012 ¶83; Ex. 1015 ¶¶115-34. That POSA would have been motivated to develop a castor oil-based formulation that, like Howell, solubilized fulvestrant at a concentration of 50 mg/ml.<sup>5</sup> See *In re ICON Health & Fitness*, 496 F.3d 1374, 1380 (Fed. Cir. 2007) (“Any need or problem known in the field of endeavor at the time of the invention and addressed by the patent can provide a reason for combining the elements in the manner claimed”).

The way to develop that formulation was readily available to a POSA, as reflected in the opinion provided by AstraZeneca’s Dr. Gellert during the prosecution of a related patent.<sup>6</sup> See *Randall Mfg. v. Rea*, 733 F.3d 1355, 1362 (Fed. Cir. 2013). There, Dr. Gellert opined during prosecution that the skilled formulator would have tried “to formulate an intramuscular (IM) injection that would provide for the satisfactory sustained release of fulvestrant...and would have a target fulvestrant content of at least 45 mg/mL.” Ex. 1020 ¶11.

---

<sup>5</sup> It was necessary to achieve this minimum concentration because that concentration results in the injection of 5 ml of solution—the maximum that can be injected intramuscularly. See Ex. 1012 ¶173; Ex. 1020 ¶11.

<sup>6</sup> The Federal Circuit has previously held that “statements during prosecution” of related applications are “applicable” to parent applications. See *Microsoft Corp. v. Multi-Tech Sys., Inc.*, 357 F.3d 1340, 1349-50 (Fed. Cir. 2004).

To achieve that target solubility, the formulator would have performed a solubility screen and “would have selected castor oil as the oil vehicle because of the higher solubility of fulvestrant in castor oil relative to the other oils tested.” *Id.* ¶17. According to Dr. Gellert, a POSA would have also recognized “ethanol and/or benzyl alcohol...as the best co-solvent candidates for raising the fulvestrant solubility to the 45 mg/mL target.” *Id.* ¶21. AstraZeneca has conceded the same. *See* Ex. 1046 at 0156, 0158. Thus, the only formulation excipient that AstraZeneca contends is novel is benzyl benzoate. Ex. 1020 ¶25.

But any such claim is directly undermined by the routine solubility screen described by Dr. Gellert. *Id.* ¶16. Such a routine screen would confirm to a POSA that castor oil, benzyl alcohol, and ethanol could not solubilize fulvestrant at the target 50 mg/ml concentration. *See* Ex. 1020 at 0016. Thus, a POSA would have been motivated to add another co-solvent to the formulation.

Benzyl benzoate would have been the logical choice. Indeed, benzyl benzoate is the third best co-solvent for solubilizing fulvestrant—after only ethanol and benzyl alcohol. Ex. 1012 ¶113. And as AstraZeneca’s Dr. Gellert noted, “a number of the commercialized formulations that would have been identified in [a] literature review (including the castor oil-based formulations) have a substantial benzyl benzoate component.” Ex. 1020 ¶18. In fact, *every castor oil-based formulation that Dr. Gellert identifies contains benzyl benzoate.* *Id.* ¶18; *see also*

Ex. 1012 ¶111. Thus, AstraZeneca's purported "surprising" discovery concerning benzyl benzoate is again undermined by the contemporaneous record.

2. A POSA Would Have A Reasonable Expectation of Success in Developing a Formulation to Achieve the Howell Results.

AstraZeneca's arguments concerning reasonable expectation of success fail for similar reasons. As an initial matter, a POSA would recognize that co-solvents may operate synergistically, with each solvent helping to solubilize a different part of the target molecule. *Id.* ¶70. Thus, a POSA would have reasonable expectation of success in combining benzyl benzoate (known for its ability to solubilize steroids in castor oil and used in numerous steroidal formulations) with the other excipients that AstraZeneca concedes are obvious. *Id.* ¶158.

Moreover, the precise amounts of each claimed excipient are well within the ranges disclosed in the art. In particular, the FDA's Inactive Ingredient Guide ("IIG") provides formulators with a list of all excipients (by route of administration and concentration) approved for use in commercially marketed formulations. As Dr. Gellert explains, "a knowledge of which excipients have been deemed safe by the FDA or are already present in a marketed product provides increased assurance to the formulator that these excipients will probably be safe for their new drug product." Ex. 1020 ¶14.

The IIG confirms that the recited excipient concentrations are presumptively

obvious. Indeed, the IIG shows that ethanol had been used up to 11%, benzyl alcohol had been used up to 15%, and benzyl benzoate had been used up to 46% for IM injections. Ex. 1012 ¶124; Ex. 1080 at 0008, 0014-15. A POSA would be motivated to stay within those ranges because FDA had already deemed them safe for IM administration. Thus, because the amounts claimed all fall within disclosed ranges, they are presumptively obvious. *See Iron Grip Barbell Co. v. USA Sports, Inc.*, 392 F.3d 1317, 1322 (Fed. Cir. 2004) (“[W]here there is a range disclosed in the prior art, and the claimed invention falls within that range, there is a presumption of obviousness”).

Additionally, during prosecution, the Examiner concluded that “the optimization of parameters such as the *amount of excipients*...is obvious as being within the skill of the artisan, absent evidence to the contrary.” Exhibit 1046 at 0163. AstraZeneca never offered contrary evidence or disputed this conclusion, which aligns with Federal Circuit law. *See In re Applied Materials, Inc.*, 692 F.3d 1289, 1295 (Fed. Cir. 2012) (“It is not inventive to discover the optimum or workable ranges by routine experimentation.”).

AstraZeneca’s attempts to distance itself from these clear findings during prosecution are meritless. *First*, AstraZeneca suggests that a formulation can never be obvious until it is tested *in vivo*. Ex. 1017 at 0046-49. But “obviousness cannot be avoided simply by a showing of some degree of unpredictability in the art so

long as there was a reasonable probability of success.” *Pfizer, Inc. v. Apotex, Inc.*, 480 F.3d 1348, 1364 (Fed. Cir. 2007). And here there was a reasonable probability of success because the prior art taught that benzyl benzoate would improve the solubility of fulvestrant in castor oil. Thus, the POSA would have reasonably expected that a formulation with benzyl benzoate could be developed that could meet the target solubility of 50 mg/ml and achieve the favorable results of Howell.

*Second*, AstraZeneca and Dr. Gellert assert that a POSA would have been motivated to use *less* benzyl alcohol. Ex. 1020 ¶23. But benzyl alcohol was frequently used at a 10% concentration for its “anesthetic properties which are exploited in some parenterals.” Ex. 1079 at 0006. Such anesthetic properties would have been desirable here given the potential injection-site pain caused by a 5 ml injection volume. Ex. 1012 ¶123.

For all these reasons, a POSA would have a reasonable expectation of success in developing a formulation to achieve the results described in Howell.

3. Every Limitation Is Disclosed By Howell And The Knowledge of a POSA.

As described above and set forth in the claim chart below, claims 1, 2, 5, and 9 are rendered obvious by Howell in view of the knowledge of a POSA.

Claim 1	Howell
(1)(1) A method of treating a hormonal	Howell discloses this limitation. Ex. 1012 ¶¶77, 83, 149-150; Ex. 1013 ¶¶79-80, 92-94, 96; Ex. 1015 ¶¶97-98,

dependent benign or malignant disease of the breast or reproductive tract	115, 118-120, 134. Howell states: “We have assessed the pharmacokinetics, pharmacological and anti-tumour effects of the specific steroidal anti-oestrogen ICI 182780 in 19 patients with advanced breast cancer resistant to tamoxifen.” Ex. 1007 at 0001, 0006-0007.
(1)(2) by administration to a human in need of such treatment an intra-muscular injection	Howell discloses this limitation. Ex. 1007 at 0001-2 (“ICI 182780 was administered as a long-acting formulation contained in a castor oil based vehicle by monthly i.m. injection (5 ml) into the buttock.”); Ex. 1012 ¶¶78, 80, 151-152; Ex. 1013 ¶¶81, 93; Ex. 1015 ¶¶99, 132, 134.
(1)(3) of a pharmaceutical formulation comprising fulvestrant	Howell discloses this limitation. Ex. 1007 at 0001-0009; Ex. 1012 ¶¶77-83, 151-52; Ex. 1013 ¶¶79-81; Ex. 1015 ¶¶97-99, 134; <i>see also</i> citations and analysis above regarding claims 1(1) and (2)).
(1)(4) a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation	<p>While Howell does not expressly disclose this formulation, a POSA would have understood that this formulation is necessary to solubilize and administer the pharmaceutical formulation. Ex. 1012 ¶¶36-40, 88-92, 104-127, 146-147, 158-160; Ex. 1013¶¶16, 36-38; 4244; Ex. 1015 ¶¶54-58, 134-156, 186.</p> <p>The ‘122 patent concedes that a number of prior art steroidal formulations included “additional excipients such as benzyl benzoate, benzyl alcohol and ethanol.” Ex. 1001 at 2:61-65.</p> <p>AstraZeneca’s formulation scientist, Dr. Gellert, opined that it would have been routine experimentation for a POSA to adjust prior art formulations to achieve the claimed percentages. To do so, the POSA would have looked to prior art formulations and combinations of excipients. Ex. 1020 ¶¶14-16, 18-19, 21-23. Thus, as the PTO found during prosecution, a POSA “<i>would have been motivated to employ benzyl benzoate, ethanol, castor oil, and benzyl alcohol, in the herein claimed weight percent, with fulvestrant, in the dosage</i></p>

	<p><i>herein....</i>” Ex. 1006 at 0538; Ex. 1012 ¶¶27, 36-40.</p> <p>A POSA would understand that solubilizing steroid hormones in oil provides the preferred slow release and that “it was necessary to add compatible and non-irritating co-solvents. Such additions consisted of benzyl benzoate, benzyl alcohol, ethyl lactate, ethyl oleate, etc.” Ex. 1033 at 0002; <i>see also</i> Ex. 1018 at 0027.</p> <p>A POSA would also arrive at the claimed amounts of co-solvents by routine experimentation. Ex. 1012 ¶¶108-127; Ex. 1015 ¶¶186.</p>
1(5) and a sufficient amount of castor oil vehicle	Howell discloses this limitation. Ex. 1007 at 0002 (“ICI 182780 was administered as a long-acting formulation contained in a castor oil-based vehicle.”); Ex. 1012 ¶¶78, 83, 153-154; Ex. 1013 ¶¶81, 96; Ex. 1015 ¶¶99, 134.
1(6) whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml <sup>-1</sup> is attained for at least 2 weeks after injection.	Howell discloses this limitation. Ex. 1007 at 0003-0004; Ex. 1012 ¶¶80-83, 155-157; Ex. 1013 ¶¶82-84, 92-96; 98; Ex. 1015 ¶¶132-34; <i>see also</i> citations and analysis above in §§ VIII(A)(1).
<b>Claim 2</b>	<b>Howell</b>
2(1) The method as claimed in claim 1 wherein the benign or malignant disease is breast cancer	Howell discloses this limitation. Ex. 1007 at 0001; Ex. 1012 ¶¶77, 83, 149-150, 161-163; Ex. 1013 ¶¶79-80; Ex. 1015 ¶¶97-98, 115, 134; <i>see</i> citations and analysis above regarding claim 1(1)).
<b>Claim 5</b>	<b>Howell</b>
5(1) through 5(5)	<i>See</i> claim 1, above.
5(6) whereby the formulation comprises at least 45 mgml of fulvestrant.	Howell discloses this limitation. Ex. 1012 ¶¶77-79, 81, 83, 164-169; Ex. 1013 ¶¶51, 81; Ex. 1015 ¶¶99, 117, 130-134. For example, Howell teaches that patients received “250 mg” of fulvestrant solubilized in a 5 ml IM injection. Ex. 1007 at 0002. This corresponds to a concentration of 50 mg/ml.
<b>Claim 9</b>	<b>Howell</b>

9(1) The method as claimed in claim 5 wherein the benign or malignant disease is breast cancer.	Howell discloses this limitation for the reasons discussed above regarding claims 1(1) and 2(1). <i>See also</i> Ex. 1012 ¶¶170-172.
---	--

**B. Ground 2: Claims 1, 2, 5, and 9 Are Obvious Over Howell and McLeskey**

As explained below, each and every limitation of claims 1, 2, 5, and 9 is taught by Howell in combination with McLeskey.

1. A POSA Would Have Been Motivated to Combine Howell and McLeskey
  - a. The Target Fulvestrant Concentration in Howell Would Have Led a Skilled Formulator to McLeskey.

Together, Howell and McLeskey disclose every claim limitation, and a POSA would have been motivated to combine them. This is distinct from the argument advanced by Mylan, which used McLeskey as the lead reference, with Howell as a mere confirmatory reference. Ex. 1078 at 0060-61. And, as the Board explained, Mylan had not “adequately demonstrated that a skilled artisan had reason to *modify the teachings of McLeskey* in accord with a POSA’s knowledge of, *e.g.*, Howell 1996, or to combine the teachings of Howell 1996 and McLeskey.” Ex. 1011 at 0023. In contrast, with Howell as the lead reference—as argued here—a POSA *did* have reason to practice its teachings by selecting the castor oil-based formulation disclosed in McLeskey.

For reasons stated above, Howell’s successful use of a castor oil-based

formulation would have motivated a POSA to develop a castor oil-based formulation that could achieve the impressive results taught by Howell. Ex. 1012 ¶174; Ex. 1015 ¶185-86; Ex. 1013 ¶109. A formulator tasked with that objective would have focused on developing a castor oil-based formulation that would solubilize fulvestrant at the same concentration as Howell, *i.e.*, 50 mg/ml. Ex. 1012 ¶174. This is undisputed. *See* Ex. 1020 ¶11 (a formulator would have aimed “to formulate an intramuscular (IM) injection that would...have a target fulvestrant content of at least 45 mg/mL so as to provide a fulvestrant dose of at least 250 mg in a single 5-6 mL injection.”); *id.* ¶17 (“[T]he experienced formulator would have selected castor oil as the oil vehicle.”).

The first step in this process would have been to conduct a literature review of known fulvestrant castor oil-based formulations. Ex. 1012 ¶175. This review would have revealed just six castor oil-based formulations of fulvestrant:

- (1) Dukes ‘814 formulation – fulvestrant, 40% w/v benzyl alcohol, and castor oil at a concentration of 50 mg/ml. *See* Ex. 1047 at 11:9-11.
- (2) Osborne formulation – fulvestrant and castor oil. Ex. 1039 at 0002.
- (3) Parczyk formulation – fulvestrant, 80% v/v castor oil, and 20% v/v benzyl benzoate. Ex. 1048 at 0001.
- (4) Chwalisz formulation – fulvestrant, 25% benzyl benzoate v/v, 75% castor oil v/v. Ex. 1089 at 0003.

- (5) Wunsche formulation – fulvestrant, 20% benzyl benzoate v/v, 80% castor oil v/v. Ex. 1088 at 0002.
- (6) McLeskey formulation – fulvestrant, 10% ethanol, 10% benzyl alcohol, 15% benzyl benzoate, and castor oil at a concentration 50 mg/ml. Ex. 1008 at 0002.

Of these six castor oil-based formulations taught in the literature, only Dukes '814 and McLeskey teach fulvestrant at the target concentration of 50 mg/ml. As a result, a POSA would have focused on these two formulations. Ex. 1012 ¶180; Ex. 1015 ¶¶136-56. And, as Dr. Gellert explained to the PTO on behalf of AstraZeneca, a POSA would have rejected the Dukes '814 formulation due to its high benzyl alcohol content. Ex. 1020 ¶¶21, 24; Ex. 1001 at 3:64-4:62.

That would have left the McLeskey formulation, which includes excipients that are within pharmaceutically acceptable levels and solubilizes fulvestrant at the target concentration of 50 mg/ml. Ex. 1012 ¶182. As the only acceptable castor oil-based formulation taught in the art to solubilize fulvestrant at the target concentration, a POSA would have been motivated to select it as the leading candidate for formulating the drug.<sup>7</sup> *Id.* ¶182.

---

<sup>7</sup> Unlike Mylan, InnoPharma has shown why a POSA would have selected the McLeskey castor oil-based formulation. *See* Ex. 1011 at 0023-24.

Thus, this is a classic case for obviousness under the controlling law: there were a “finite number of identified, predictable solutions” to a problem, and a POSA had “good reason to pursue the known options within his or her technical grasp.” *KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 402-03 (2007).

b. The Record Confirms the Motivation to Combine Howell and McLeskey.

The Mylan IPR left unresolved questions about the motivation to combine McLeskey and Howell. Those questions are answered here and eliminate AstraZeneca’s claim that “critical differences between Howell 1996 and McLeskey would have suggested to a skilled artisan that the references should not be combined.” Ex. 1017 at 0067. The record here shows that the POSA had every reason to combine these references.

As a threshold matter, McLeskey is “analogous art” for purposes of the obviousness analysis. Ex. 1015 ¶¶29, 114. Indeed, the Federal Circuit has explained that a prior art reference is analogous—and therefore readily combinable—where “the reference...is reasonably pertinent to the particular problem with which the inventor is involved.” *In re Ethicon, Inc.*, 844 F.3d 1344, 1349 (Fed. Cir. 2017).

Here, Howell would motivate a POSA to develop a castor oil-based formulation that could solubilize fulvestrant at the target concentration. McLeskey

is “reasonably pertinent to [this] particular problem,” *id.*, because it specifically discloses a castor oil-based formulation with the target concentration of fulvestrant. Ex. 1012 ¶182. Moreover, a POSA would recognize that the McLeskey formulation was pharmaceutically acceptable—it used only recognized pharmaceutical excipients in concentrations that had been previously approved by FDA for IM administration. *Id.* ¶182.

Indeed, the motivation to combine Howell and McLeskey is more pronounced than in the Federal Circuit’s decision in *Ethicon*, which affirmed the Board’s obviousness finding. 844 F.3d at 1347-48. There, the Board found the cardiac stent claims obvious over a combination that included a reference, Lo. *Id.* at 1348. Lo taught the copolymer weight ratio recited in the cardiac stent claims, but was “directed to coatings for harsh, industrial applications.” *Id.* at 1348, 1350. The Federal Circuit rejected the patentee’s argument that Lo was non analogous art, and upheld the Board’s finding that “the skilled worker would have reasonably consulted Lo to determine the optimal concentrations for each component, *even if Lo does not teach the use of [those components] for medical implants.*” *Id.* at 1348.

Here, in contrast, McLeskey *did* teach that fulvestrant inhibited estrogenic activity—and so is much closer art than the invalidating Lo patent in *Ethicon*, which had nothing to do with medical devices. *See id.* at 1350. Yet the Board and

the Federal Circuit agreed that a POSA would be motivated to combine Lo with references in the medical device field. If Lo was analogous, McLeskey necessarily is analogous also.

Moreover, the alleged differences between McLeskey and Howell would not discourage a POSA from combining them. Each alleged difference speaks only to whether a POSA, looking at McLeskey, would consult Howell. But the question here is whether a POSA considering Howell would look to McLeskey for its pharmaceutically acceptable formulation capable of dissolving fulvestrant at the target concentration of 50 mg/ml. The POSA would not need to rely on McLeskey to teach pharmacokinetics, the route of administration, the dose, or any other topics already covered by Howell. The alleged differences are, therefore, irrelevant to the motivation to combine the references, as explained in further detail below:

- **Monthly IM Injection v. Weekly SC Injection:** The starting point of the obviousness analysis, Howell, expressly teaches monthly IM administration. Ex. 1007 at 0001-2. Moreover, a POSA would not discard McLeskey because it utilized a SC route of administration in mice. Ex. 1012 ¶210; Ex. 1015 ¶141. Instead, the POSA would recognize that depot formulations are administered to mice subcutaneously because mice generally do not have adequate muscle mass for regular IM injections. Ex. 1012 ¶210. A POSA would appreciate these differences and would not—as AstraZeneca

asserts—seek to “extrapolate” the results of SC administration to IM administration. Ex. 1017 at 0027.

- **Humans v. Mice:** AstraZeneca’s argument is directly contrary to Federal Circuit law. Indeed, in *Alcon Research, Ltd. v. Apotex Inc.*, the Court rejected an attempt to distinguish prior art on the ground that it was tested in animals because the patent was also solely based on animal testing. 687 F.3d 1362, 1369 (Fed. Cir. 2012). The same reasoning applies here. Indeed, the ‘122 patent discloses *no* human testing, and relies only on 5 days of rabbit data. Ex. 1001 at Figure 1.
- **250 mg/5 ml/Month Dose in Humans v. 5 mg/0.01ml/Week in Mice:** As Dr. Harris explains, AstraZeneca’s calculation is wrong by orders of magnitude. *See* Illum Decl. ¶151 (calculating equivalent dose as 12,000 mg per human). In reality, the mouse dose is approximately equivalent to 400 mg/month in humans. Ex. 1015 ¶¶170-72.
- **Hormone Independent v. Dependent Cancer:** In order to effectively treat breast cancer, a POSA would assess hormone-independent and hormone-dependent pathways together. Ex. 1014 ¶¶65-66. This is particularly true for second-line therapies such as fulvestrant. *Id.* ¶¶65-66. When a patient has already failed one therapy, the skilled clinician would need to understand the mechanism of action of the cancer to appropriately treat it in

a second-line setting. *Id.* ¶¶66; Ex. 1015 ¶¶76.

- **Lack of Pharmacokinetic Data in McLeskey:** As noted above, Howell—which includes fulsome pharmacokinetic data—is the starting point, not McLeskey. Moreover, AstraZeneca’s assertion that a POSA would disregard the formulation disclosed in McLeskey because of a lack of pharmacokinetic data has been rejected by the Federal Circuit. *See Duramed Pharms., Inc. v. Watson Labs., Inc.*, 413 F. App’x 289, 294 (Fed. Cir. 2011) (a reference “is prior art for all that it discloses, and there is *no requirement* that a teaching in the prior art be *scientifically tested*, or even guarantee success, before providing *a reason to combine*”) (internal citations omitted).

AstraZeneca, therefore, failed to identify any “critical difference” that would have distracted from the clear motivation to combine Howell and McLeskey.

2. A POSA Would Have A Reasonable Expectation of Success in Administering the McLeskey Formulation Intramuscularly to Achieve the Results Reported in Howell

A POSA would also have had a reasonable expectation that the McLeskey formulation could be administered by IM injection, as taught in Howell, in order to achieve the successful antitumor results of Howell. Ex. 1015 ¶¶161-74. The evidence submitted with this Petition sets this Petition apart from the prior Mylan IPRs. *See* Ex. 1011 at 0028.

The goal in developing a sustained-release depot formulation, like the one used in Howell, is to maintain the desired minimum serum concentration of the drug over the length of time between injections. Ex. 1012 ¶185. Howell shows that therapeutic levels of fulvestrant can be maintained over 28 days by a once-monthly injection of a castor oil-based fulvestrant solution with a fulvestrant concentration of 50 mg/ml. *See supra* § VIII(A)(1). Thus, to achieve the results in Howell, the skilled formulator would focus on ensuring that the day 28 serum concentration (*i.e.*, the last day before the next injection) would stay above the minimum therapeutic level.

Howell does not report any toxicity at the doses needed to reach minimum serum concentrations taught by that reference. *See* Ex. 1007 at 0004. As a result, a POSA would not have been concerned with the maximum serum concentrations obtained by the formulation. Ex. 1012 ¶185; Ex. 1013 ¶¶82-84; Ex. 1015 ¶¶131-32. This is consistent with the claims, which recite only minimum plasma concentrations.

A formulator would understand that castor oil is the rate limiting factor in both the McLeskey and Howell formulations.<sup>8</sup> Ex. 1012 ¶187; Ex. 1076 at 0001

---

<sup>8</sup> A POSA would recognize that both formulations were solutions. Ex. 1012 ¶¶197-201.

(“Rate-limiting step is the liberation of drug from the oil depot”); Ex. 1077 at 0001. This means that a POSA would expect the fulvestrant and castor oil in the formulation to be absorbed slowly from the depot since neither ingredient is water soluble. *See* Ex. 1012 ¶192; Ex. 1072 at 0002.

In contrast, a POSA would understand that the other excipients in the McLeskey formulation—ethanol, benzyl benzoate, benzyl alcohol—would not be expected to affect the minimum serum concentrations at day 28 because they would dissipate quickly from the injection depot. Ex. 1012 ¶194; Ex. 1013 ¶¶117, 119. The ‘122 patent itself confirms this rapid dissipation. *See* Ex. 1001 at 8:61-65; 8:47-53; 8:57-60.

As a result, the fact that Howell and McLeskey disclose the same absorption rate-limiting excipient (*i.e.*, castor oil) means that a POSA would have had a reasonable expectation of success that the McLeskey formulation could achieve the same minimum serum concentrations achieved by Howell, and, in turn, the same promising results. Ex. 1012 ¶194.

During prosecution of the ‘680 patent, AstraZeneca tried to distinguish McLeskey through the declaration of Dr. Sawchuk. But Dr. Sawchuk did not address Howell, so his analysis is missing the motivation that would have caused one to look at McLeskey in the first place. Moreover, Dr. Sawchuk—who is not a formulator—repeatedly contradicted the declaration of Dr. Gellert, the formulator

who worked on fulvestrant.

But, apart from these flaws that permeate Dr. Sawchuk's testimony, the particular points in his testimony also fail to render the challenged claims nonobvious. Unlike the Mylan IPR, which "failed to adequately address the expert testimony and other evidence cited in the Sawchuk § 1.132 Declaration," Ex. 1011 at 0027, InnoPharma's experts have refuted each of Dr. Sawchuk's points in their Declarations as summarized below:

- **Alleged "Failure" in McLeskey:** As Dr. El-Ashry explains, *see* § VIII(A)(2), fulvestrant worked exactly as intended in McLeskey and this would be understood by a POSA. Exhibit 1014 ¶¶44-49.
- **No Preference for Castor Oil:** Dr. Sawchuk's opinion directly contradicts Dr. Gellert's opinion. Dr. Gellert opines that "the experienced formulator *would have selected castor oil as the oil vehicle* because of the higher solubility of fulvestrant in castor oil relative to the other oils tested." Ex. 1020 ¶¶13, 17; Ex. 1012 ¶204.
- **Preference for Arachis Oil Suspension Over McLeskey Formulation:** This contradicts Dr. Gellert's Declaration. In particular, Dr. Gellert opines that "suspensions...were *not* an acceptable option for fulvestrant." Exhibit 1020 ¶¶13, 17; Ex. 1012 ¶204.
- **Preference for Dukes Castor Oil Formulation Over McLeskey**

**Formulation:** Dr. Gellert considered *and rejected* this formulation because the alcohol content was too high. Ex. 1020 ¶¶21, 24; Ex. 1012 ¶208.

- **No Clinical Data on Efficacy and Pharmacokinetics:** *First*, Howell provides clinical data and the specific motivation to use the McLeskey formulation. Ex. 1012 ¶209. *Second*, as explained above, a POSA would reasonably expect that McLeskey would have the same or very similar pharmacokinetics at day 28 as Howell. Ex. 1012 at § IX(D)(2). *Third*, as a matter of law, the “blood serum concentration resulting from administering a [drug] is an inherent property of the formulation, and an obvious formulation cannot become nonobvious simply by administering it to a patient and claiming the resulting serum concentrations.” *Santarus, Inc. v. Par Pharm., Inc.*, 694 F.3d 1344, 1354 (Fed. Cir. 2012).
- **SC Route:** *First*, Howell expressly teaches that IM injections of fulvestrant are successful. Ex. 1007 at 0001. *Second*, depot injections are generally given SC in mice because mice lack the muscle mass for IM injection. Ex. 1012 ¶210; Ex. 1015 ¶141. *Third*, it was known that “[c]linically, [fulvestrant] must be given by depot intramuscular injection.” Ex. 1009 at 0002. A POSA would not be dissuaded from that route based on the SC route disclosed in McLeskey as discussed above. *See infra* 59-60.

- **Safety Not Proven Without Clinical Trials:** This is wrong as a matter of law and fact, as explained *supra* § VIII(B)(2). See also *Cubist Pharms., Inc. v. Hospira, Inc.*, 805 F.3d 1112, 1124-25 (Fed. Cir. 2015) (finding reasonable expectation of success without clinical trials), *cert. denied*, 136 S. Ct. 2393 (2016).
- **Excipient Impact on Pharmacokinetics Profile:** As Dr. Burgess explains, the source cited by Dr. Sawchuk, Ex. 1037, confirms that the excipients used in a castor oil-based formulation do not affect the minimum serum concentration obtained on day 28. Ex. 1012 ¶215; Ex. 1013 ¶¶177-86.
- **V/V Versus W/V Units:** *First*, the Board previously accepted that the McLeskey formulation matches the formulation recited in the claims. Ex. 1011 at 0023. *Second*, formulators prefer to use w/v measurements because measuring by weight is more accurate than measuring by volume, which varies with temperature and pressure. Ex. 1012 ¶221. *Third*, USP rules teach solids dissolved in liquids—as is the case with fulvestrant—are understood to refer to w/v measurements if no qualification is provided. *Id.* ¶222. *Fourth*, AstraZeneca’s own expert, Dr. Gellert, uses percentages without units to refer to w/v measurements, not v/v as Dr. Sawchuk asserts. *Id.* ¶223. *Fifth*, even if McLeskey were ambiguous as to units, it was obvious to try both. *Id.* ¶224.

3. Each and Every Limitation Is Disclosed By the Combination of Howell and McLeskey

As described above and set forth in the claim chart below, claims 1, 2, 5, and 9 are rendered obvious by Howell and McLeskey.

Claim 1	Howell and McLeskey
(1)(1) A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(1). <i>See also</i> Ex. 1012 ¶¶228-229.
(1)(2) by administration to a human in need of such treatment an intra-muscular injection	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(2). <i>See also</i> Ex. 1012 ¶230; Ex. 1014 ¶¶59-61.
(1)(3) of a pharmaceutical formulation comprising fulvestrant	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(3). <i>See also id.</i>  McLeskey also discloses this limitation. Ex. 1008 at 0001, 0004-0005; Ex. 1012 ¶¶85, 88, 231-232; Ex. 1013 ¶87; Ex. 1014 ¶¶42-43; Ex. 1015 ¶104, 149-56.
(1)(4) a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(4).  McLeskey discloses this limitation. Ex. 1012 ¶¶88-92, 234-236; Ex. 1013 ¶¶87, 117; Ex. 1014 ¶¶42-43; Ex. 1015 ¶¶104, 152, 156. McLeskey discloses the same formulation as claimed, i.e., fulvestrant formulated “in a vehicle of 10% ethanol, 15% benzyl benzoate, 10% benzyl alcohol, brought to volume with castor oil.” Ex. 1008 at 0002.
1(5) and a sufficient amount of castor oil	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(5). McLeskey also

vehicle	discloses this limitation. Ex. 1008 at 0002; Ex. 1012 ¶¶88-92 231-232; Ex. 1013 ¶87; Ex. 1014 ¶¶42-43; Ex. 1015 ¶¶104, 152-53.
1(6) whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml <sup>-1</sup> is attained for at least 2 weeks after injection.	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(6). <i>See also</i> Ex. 1012 ¶233.
<b>Claim 2</b>	<b>Howell and McLeskey</b>
2(1) The method as claimed in claim 1 wherein the benign or malignant disease is breast cancer	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claims 1(1) and 2(1). <i>See also</i> Ex. 1012 ¶237-239.
<b>Claim 5</b>	<b>Howell and McLeskey</b>
5(1) through 5(5)	<i>See</i> claim 1, above. <i>See also</i> Ex. 1012 ¶240-244.
5(6) whereby the formulation comprises at least 45 mgml of fulvestrant.	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 5(6). McLeskey also discloses this limitation. Ex. 1012 ¶¶87-92, 240-244; Ex. 1013 ¶87; Ex. 1008 at 0002; Ex. 1014 ¶¶42-43; Ex. 1015 ¶¶104, 152.
<b>Claim 9</b>	<b>Howell and McLeskey</b>
9(1) The method as claimed in claim 5 wherein the benign or malignant disease is breast cancer.	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claims 1(1), 2(1) and 9(1). <i>See also</i> Ex. 1012 ¶245-247.

**C. Ground 3: Claims 1, 2, 5, and 9 Are Obvious Over Howell, McLeskey, and O'Regan**

As explained below, each and every limitation of claims 1, 2, 5, and 9 is taught by Howell, McLeskey, and O'Regan.

1. A POSA Would Have Been Motivated to Combine Howell, McLeskey, and O'Regan

O'Regan specifically cites Howell as confirming that fulvestrant “has shown promising results clinically in Europe, with high response rates of almost 70% in tamoxifen-failed, advanced breast cancer.” Ex. 1009 at 0002. Thus, a POSA would have been motivated by Howell to look to the study reported in O'Regan, especially given that O'Regan tests the same compound. Ex. 1015 ¶¶114, 157-60. And, as explained above, a POSA would have been motivated to combine McLeskey with Howell as well.

Despite testing fulvestrant subcutaneously in mice in her study, O'Regan teaches that “[c]linically, [fulvestrant] *must be given by depot intramuscular injection....*” Ex. 1009 at 0002. The results of O'Regan would have thus motivated a POSA to administer the McLeskey formulation intramuscularly.

2. A POSA Would Have A Reasonable Expectation of Success in Combining Howell, McLeskey, and O'Regan

The Board faulted Mylan's IPR on the ground that it “provided insufficient evidence that one of ordinary skill in the art would have reasonably expected the physiologic effects of the claimed combination upon intramuscular injection to human patients” because McLeskey involved SC injections to mice. Ex. 1011 at 0028. But O'Regan, in combination with Howell and McLeskey, is strong evidence that a POSA would expect success in using the McLeskey formulation

intramuscularly in humans. Ex. 1015 ¶¶161-87.

While O'Regan also reported a study of fulvestrant injected subcutaneously into mice, Ex. 1009 at 0002, it clarified that “*clinically*, [fulvestrant] must be given by *depot intramuscular injection* because of low oral potency.” *Id.* at 0002. The rationale for IM injection in humans is that the relatively large injection volume (5 ml) required to achieve satisfactory blood concentrations exceeds the allowable volume for SC administration. Ex. 1012 ¶255. However, in mice, depot injections generally have to be administered subcutaneously because mice lack acceptable muscle mass for IM injection. *Id.* ¶254.

Moreover, a skilled formulator would have known that the IM and SC routes of administration are similar, although SC administration generally results in slower absorption. *Id.* ¶253. Because of the similarities, the same formulation may be administered either subcutaneously or intramuscularly. *Id.* ¶253; Ex. 1015 ¶¶167-71.

Therefore, a POSA following the teachings of O'Regan, in combination with Howell and McLeskey, would have a reasonable expectation of success in administering the McLeskey formulation intramuscularly in humans.

3. Each and Every Limitation Is Disclosed By the Combination of Howell, McLeskey, and O'Regan

As described above and set forth in the claim chart below, claims 1, 2, 5, and

9 are rendered obvious by Howell, McLeskey, and O'Regan.

Claim 1	Howell, McLeskey, and O'Regan
(1)(1) A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(1). <i>See also</i> Ex. 1012 ¶¶263-264.
(1)(2) by administration to a human in need of such treatment an intra-muscular injection	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(2). O'Regan also expressly discloses IM administration in humans. Ex. 1009 at 0002; Ex. 1012 ¶¶96, 255-256, 265-; Ex. 1013 ¶¶89; Ex. 1015 ¶¶108, 158. <i>see also</i> citations and analysis above in §§ IX.C.1. and IX.C.2.
(1)(3) of a pharmaceutical formulation comprising fulvestrant	Howell and McLeskey disclose this limitation for the reasons discussed above in Grounds 1 and 2 regarding claim 1(3). <i>See also</i> Ex. 1012 ¶263.
(1)(4) a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation	Howell and McLeskey disclose this limitation for the reasons discussed above in Grounds 1 and 2 regarding claim 1(4). <i>See also</i> Ex. 1012 ¶268.
1(5) and a sufficient amount of castor oil vehicle	Howell and McLeskey disclose this limitation for the reasons discussed above in Grounds 1 and 2 regarding claim 1(5). <i>See also</i> Ex. 1012 ¶266.
1(6) whereby a therapeutically significant blood plasma fulvestrant concentration of at	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 1(6). <i>See also</i> Ex. 1012 ¶267.

least 2.5 ngml <sup>-1</sup> is attained for at least 2 weeks after injection.	
<b>Claim 2</b>	<b>Howell, McLeskey, and O'Regan</b>
2(1) The method as claimed in claim 1 wherein the benign or malignant disease is breast cancer	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claims 1(1) and 2(1)). <i>See also</i> Ex. 1012 ¶¶270-272.
<b>Claim 5</b>	<b>Howell, McLeskey, and O'Regan</b>
5(1) through 5(5)	<i>See</i> claim 1, above
5(6) whereby the formulation comprises at least 45 mgml of fulvestrant.	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claim 5(6). McLeskey also discloses this limitation for the reasons discussed above in Ground 2 regarding claim 5(6). <i>See also</i> Ex. 1012 ¶¶273-277.
<b>Claim 9</b>	<b>Howell, McLeskey, and O'Regan</b>
9(1) The method as claimed in claim 5 wherein the benign or malignant disease is breast cancer.	Howell discloses this limitation for the reasons discussed above in Ground 1 regarding claims 1(1), 2(1) and 9(1). <i>See also</i> Ex. 1012 ¶¶278-280.

**X. SECONDARY CONSIDERATIONS FAIL TO OVERCOME THE EVIDENCE OF OBVIOUSNESS**

AstraZeneca has asserted two secondary considerations: long-felt need and unexpected results. Ex. 1017 at 0075-77. AstraZeneca's alleged evidence fails because there is no nexus and, even if there were, AstraZeneca's purported evidence is insufficient.

**A. There Is No Nexus to the Claimed Invention**

AstraZeneca's purported secondary considerations are attributable to the

fulvestrant *compound*, which is not a novel aspect of the invention.<sup>9</sup> See Ex. 1016; Ex. 1015 ¶¶190-94. As a result, there is no nexus. *In re Huai-Hung Kao*, 639 F.3d 1057, 1068 (Fed. Cir. 2011).

*First*, industry development of fulvestrant was blocked by AstraZeneca's compound patent, which expired in 2007, long after the priority date of the '680 patent. See Ex. 1016; cf. *Merck & Co. v. Teva Pharms. USA, Inc.*, 395 F.3d 1364, 1377 (Fed. Cir. 2005). Moreover, Dr. Robertson claimed that fulvestrant met the "need to improve on the current standard of care," but that is attributable to the fulvestrant compound, not to the challenged claims. Robertson Decl. ¶198.

*Second*, Dr. Robertson's purported evidence of unexpected safety and efficacy—for example, the lack of bone loss—is also attributable to the compound, not the claimed method. Ex. 1015 ¶193.

*Third*, Dr. Robertson cannot create a nexus based on clinical trials that post-date the claimed invention and utilize a 500 mg dose when the claims do not recite a 500 mg dose. Robertson Decl. ¶215. See *Allergan, Inc. v. Apotex Inc.*, 754 F.3d 952, 965 (Fed. Cir. 2014) ("evidence of non-obviousness *must be commensurate*

---

<sup>9</sup> Indeed, AstraZeneca's formulation expert, Dr. Illum, seems to concede as much. Illum Decl. ¶¶123-125 (arguing that Howell concerns the fulvestrant molecule, not the formulation or method of treatment used).

*in scope with the claims*”) (citation omitted), *cert. denied*, 135 S. Ct. 956 (2015).

*Fourth*, Dr. Robertson’s citation to FDA’s approval of Faslodex<sup>®</sup> (Robertson Decl. ¶222) cannot confer nexus, *see AstraZeneca LP v. Breath Ltd.*, 603 F. App’x 999, 1003 (Fed. Cir. 2015). *Fifth*, Dr. Illum’s analysis ignores Howell and McLeskey. She thus failed to compare the claimed inventions to the closest prior art as required. *See Pfizer, Inc. v. Apotex, Inc.*, 480 F.3d 1348, 1370 (Fed. Cir. 2007).

**B. AstraZeneca’s Secondary Considerations Arguments Fail**

Regardless of nexus, AstraZeneca’s secondary considerations arguments do not comport with the controlling legal standard and are undermined by AstraZeneca’s own documents and admissions.

**1. AstraZeneca Cannot Show Long-Felt Need**

According to Dr. Robertson, fulvestrant filled a “need to improve on the current standard of care and also extend the sequence of endocrine therapies.” Robertson Decl. ¶198. This argument fails because: (i) there is no nexus to the claims; and (ii) because long-felt need is assessed as of the filing date of patent, not years after the fact. *See Ex. 1015 ¶¶189-99; Perfect Web Techs., Inc. v. InfoUSA, Inc.*, 587 F.3d 1324, 1332–33 (Fed. Cir. 2009). And all of the evidence Dr. Robertson cites post-dates the ‘122 patent. Robertson Decl. ¶199.

2. The Results Were Not Unexpected

AstraZeneca similarly cannot show unexpected results because every result was fully expected by a POSA at the time of the invention. *See Pfizer*, 480 F.3d at 1370-71.

a. Dr. Robertson's Arguments Are Contradicted By His Own Published Work.

Dr. Robertson's attempts to re-cast fulvestrant as an "unproven" therapy are meritless. *First*, as explained above, fulvestrant was known to be effective in treating hormone-dependent cancer long before the priority date of the patent. *See supra* §§ VIII(B)(1).

*Second*, Dr. Robertson's published work confirms that fulvestrant was known to have a favorable safety profile. *See Ex. 1007* at 0004. In particular, it was known that fulvestrant does not affect bone density in animal models, so it is not surprising that the same held true in humans. *See Ex. 1031* at 0007.

*Third*, Dr. Robertson's claim that it was surprising that "the injections of the invention method are *well tolerated locally*" is again contradicted by Dr. Robertson's published work. Using that exact phraseology, Howell confirmed that fulvestrant "appeared *well tolerated locally* at the site of injection...." *Ex. 1007* at 0004; *see also Ex. 1032* at 0012. In short, these results would have been expected.

b. The Release Profile and Effect of Benzyl Benzoate Were Expected

In addition to being disclosed by McLeskey and Howell, the effect of benzyl benzoate and the release profile would have been expected by a POSA. As explained above, a POSA would have expected the addition of benzyl benzoate to improve the solubility of the fulvestrant compound in castor oil. *See supra* § IX(A)(1); Ex. 1012 ¶113. Additionally, the release profile of the formulation would have been expected based on the known properties of castor oil. *See supra* § IX(B)(2); Ex. 1012 ¶287; Ex. 1033 at 0005.

Dr. Illum's arguments to the contrary are not persuasive. She argues that the release profile was "surprising, because aqueous suspensions caused 'extensive local tissue irritation at the injection site as well as a poor release profile.'" Illum Decl. ¶218. Aqueous suspensions, however, are not an appropriate comparison due to fulvestrant's insolubility in water. *See supra* 16; Ex. 1012 ¶¶136, 288-90. Moreover, a POSA would appreciate that "suspensions...were *not* an acceptable option for fulvestrant." Ex. 1020 ¶¶13, 17. Additionally, it was taught in the prior art that a castor oil-based vehicle did not produce extensive local tissue irritation. Ex. 1007 at 0004. Accordingly, AstraZeneca's argument fails.

**XI. CONCLUSION**

For the foregoing reasons, *inter partes* review of claims 1, 2, 5, and 9 of the

IPR2017-00904  
Petition for *Inter Partes* Review

'122 patent is requested.

Respectfully submitted,

WILEY REIN LLP

By:           /Mark Pacella, #46,974/            
Mark Pacella, Reg. No. 46,974

**CERTIFICATION OF WORD COUNT**

Pursuant to 37 C.F.R. § 42.24(c) and (d), Petitioner certifies that the word count of InnoPharma Licensing, LLC's Petition for *Inter Partes* Review (exclusive of any table of contents, table of authorities, mandatory notices under § 42.8, certificate of service or word count, or appendix of exhibits or claim listing) as measured by Microsoft Word is 13,921 words.

By: /Mark Pacella, #46,974/  
Mark Pacella, Reg. No. 46,974

IPR2017-00904  
Petition for *Inter Partes* Review

**CERTIFICATE OF SERVICE ON PATENT OWNER**  
**UNDER 37 C.F.R. § 42.105(A)**

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(b), the undersigned certifies that, on the 17th day of February 2017, a complete and entire copy of this Petition for *Inter Partes* Review, together with all supporting exhibits, was provided to the Patent Owner by mailing a copy of the same via FedEx® Priority Overnight with Saturday delivery to the following attorneys of record for the Patent Owner:

Morgan, Lewis & Bockius LLP  
1111 Pennsylvania Ave, NW  
Washington, DC 20004

And by mailing a copy of the same via FedEx® Priority Overnight with Saturday delivery to:

Filko Prugo  
O'Melveny & Myers LLP  
Times Square Tower  
7 Times Square  
New York, NY 10036

And by mailing a copy of the same via FedEx® International Priority to:

AstraZeneca AB  
Attn: General Counsel  
Vastra Malarehamnen 9  
Sodertalje SE-151 85  
Sweden

And by mailing a copy of the same via FedEx® Priority Overnight with Saturday delivery and delivering another copy via same-day courier service to:

Mark D. Sweet  
Finnegan, Henderson, Farabow, Garrett & Dunner

~~IPR2017-00904~~  
Petition for *Inter Partes* Review

---

901 New York Avenue, NW  
Washington, DC 20001

By:           /Mark Pacella, #46,974/  
Mark Pacella, Reg. No. 46,974